Document:

EX-4.4

 Exhibit 4.4 

Execution Version 
 FIFTH
AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 
 This FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT (the
“Agreement”) is made as of January 10, 2020 by and among: 
  

	1.	 Burning Rock Biotech Limited, an exempted company duly incorporated and validly existing under the Laws of the
Cayman Islands (the “Company”); 

  

	2.	 BR Hong Kong Limited, a limited liability company incorporated under the Laws of Hong Kong (the “HK
Company”); 

  

	3.	 Beijing Burning Rock Biotech Limited
(北京博宁洛克生物科技有限公司), a wholly foreign owned enterprise duly incorporated and validly existing under the Laws of the PRC (the “WFOE”);

  

	4.	 Burning Rock Biotechnology (Shanghai) Co., Ltd.
(燃石生物科技(上海)有限公司), a company duly incorporated and validly existing under the Laws of the PRC (the “Shanghai Subsidiary”);

  

	5.	 Burning Rock (Beijing) Biotechnology Co., Ltd.
(燃石(北京)生物科技有限公司), a company duly incorporated and validly existing under the Laws of the PRC (the “Beijing Subsidiary”);

  

	6.	 Guangzhou Burning Rock Dx Co., Ltd.
(广州燃石医学检验所有限公司), a company duly incorporated and validly existing under the Laws of the PRC and a wholly-owned subsidiary of the Beijing Subsidiary (the
“Guangzhou Laboratories Subsidiary”); 

  

	7.	 Guangzhou Burning Rock Biotechnology Co., Ltd.
(广州燃石生物科技有限公司), a company duly incorporated and validly existing under the Laws of the PRC and a wholly-owned subsidiary of the Beijing Subsidiary (the
“Guangzhou Biotechnology Subsidiary”); 

  

	8.	 Guangzhou Burning Rock Medical Equipment Co., Ltd.
(广州燃石医疗器械有限公司), a company duly incorporated and validly existing under the Laws of the PRC and a wholly-owned subsidiary of the Beijing Subsidiary (the
“Guangzhou Equipment Subsidiary”), together with the Shanghai Subsidiary, the Beijing Subsidiary, the Guangzhou Laboratories Subsidiary and the Guangzhou Biotechnology Subsidiary, the “Domestic Companies”, and each
a “Domestic Company”, the Domestic Companies together with the Company, HK Company and WFOE and any subsidiary or affiliate of the foregoing (if any), collectively the “Group Companies”); 

 

	9.	 The individual listed on Schedule
I-A-1 attached hereto (the “Founder”); 

  

	10.	 The entities listed on Schedule
I-A-2 attached hereto (each such entity, “Holding Entity” and, collectively, the “Holding Entities”); 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 1 

	11.	 Each of the individuals listed on Part I of Schedule I-B
attached hereto (each such individual, “Management Shareholder” and, collectively, the “Management Shareholders”, and together with the Founder and Holding Entities, the “Key Holders” and each a
“Key Holder”); 

  

	12.	 Each of the individuals listed on Part II of Schedule I-B
attached hereto; 

  

	13.	 Each of the Persons listed on Schedule I-C attached hereto (each
such Person, “A Round Financing Investor” and, collectively, the “A Round Financing Investors”); 

  

	14.	 Each of the Persons listed on Schedule I-D attached hereto (each
such Person, an “A+ Round Financing Investor” and, collectively, the “A+ Round Financing Investors”); 

  

	15.	 Each of the Persons listed on Schedule I-E attached hereto (each
such Person, a “B Round Financing Investor” and, collectively, the “B Round Financing Investors”); 

  

	16.	 Each of the Persons listed on Schedule I-F attached hereto (each
such Person, a “C Round Financing Investor” and, collectively, the “C Round Financing Investors”); and 

  

	17.	 Each of the Persons listed on Schedule I-G attached hereto (each
such Person, a “C+ Round Financing Investor” and, collectively, the “C+ Round Financing Investors”, together with A Round Financing Investors, A+ Round Financing Investors, B Round Financing Investors, C Round
Financing Investors, each an “Investor”, and collectively the “Investors”). 

RECITALS 
 WHEREAS,
the Company, OrbiMed, Casdin, the Key Holders, the WFOE, the HK Company, the Domestic Companies and the other parties thereto are each parties to the Series C+ Preferred Share Purchase Agreement dated as of December 30, 2019 (the “Purchase
Agreement”); 
 WHEREAS, C Round Financing Investors, B Round Financing Investors, A+ Round Financing Investors, A Round
Financing Investors, the Group Companies and the Key Holders and certain other parties have entered into a Fourth Amended and Restated Shareholders’ Agreement, dated January 31, 2019 (as amended, the “Prior Agreement”),
pursuant to which the Key Holders, A Round Financing Investors, A+ Round Financing Investors, B Round Financing Investors and C Round Financing Investors were granted certain registration rights, preemptive rights and other rights in connection with
the securities of the Company owned by them; 
 WHEREAS, the Purchase Agreement provides that the execution and delivery of this
Agreement shall be a condition precedent to the consummation of the transactions contemplated under the Purchase Agreement; and 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 2 

 WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to
induce OrbiMed and Casdin to invest funds in the Company pursuant to the Purchase Agreement, the Investors, the Key Holders, the HK Company and the Domestic Companies hereby agree that this Agreement shall replace the Prior Agreement, and govern
certain shareholder rights and other matters as set forth in this Agreement. 
 NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

  

	1.	 DEFINITIONS. 

For purposes of this Agreement, capitalized terms shall have the meanings set forth on Appendix A attached hereto. 

 

	2.	 REGISTRATION RIGHTS. 

The registrations rights of the Investors with respect to the Company and the rights and obligations of the Parties with respect to
registration of the Company’s Ordinary Shares are set forth on Appendix B attached hereto. Such registration rights shall be transferable to any transferee including without limitation any Affiliate, shareholder, member, or limited or
general partner of such Investor. 
 The rights set forth on Appendix B shall terminate upon the earlier of: (i) as to any
Holder, when all Registrable Securities held by such Holder (together with any Affiliate of such Holder with whom such Holder must aggregate its sales under SEC Rule 144) could be sold without restriction under SEC Rule 144 (k) within a ninety
(90) day period, and (ii) the date that is five (5) years following the consummation of a Qualified IPO. 
 No future
registration rights may be granted without consent of a majority of the Preferred Shares (voting together as a single class on an as converted basis), unless subordinate to or parri passu with any Investor’s rights. 

 

	3.	 INFORMATION AND OBSERVER RIGHTS. 

 

	3.1	 Delivery of Financial Statements. 

So long as any Investor continues to hold no less than five percent (5%) of the total issued and outstanding Preferred Shares on an as
converted and as-exercised basis (as adjusted for any share splits, share dividends, recapitalizations or the like), the Company shall, and shall cause the Group Companies to, deliver to such Investor: 

 

	 	(a)	 as soon as practicable, but in any event within ninety (90) days after the end of each financial year of
the Company, (i) an audited consolidated financial statement as of the last day of such year; (ii) an audited consolidated income statement for such year; and (iii) an audited consolidated statement of cash flows for such year; such year-end financial statements to be in reasonable detail, prepared in accordance with PRC GAAP consistently applied and in each case setting forth in comparative form figures for the previous year and audited and
certified by an accredited accounting firm or any other independent public accountants of internationally recognized standing selected by the Company according to Section 7.1(b)(xv); 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 3 

	 	(b)	 as soon as practicable, but in any event within thirty (30) days after the end of each quarter of each
financial year of the Company, (i) an unaudited consolidated balance sheet as of the last day of such quarter; (ii) an unaudited consolidated income statement for such quarter; and (iii) an unaudited consolidated statement of cash
flows for such quarter; 

  

	 	(c)	 as soon as practicable, but in any event within thirty (30) days after the end of each month, (i) an
unaudited consolidated balance sheet as of the last day of such month; (ii) an unaudited consolidated income statement for such month; and (iii) an unaudited consolidated statement of cash flows for such month; 

 

	 	(d)	 as soon as practicable, but in any event forty-five (45) days prior to the end of each fiscal year, an
annual consolidated budget for the next fiscal year to be submitted to the Board for approval (collectively, the “Budget”), prepared on a monthly basis including, revenues, expenses, cash position, balance sheets and sources and
applications of funds statements (including any anticipated or planned capital expenditure or borrowings) for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company; 

 

	 	(e)	 with respect to the financial statements called for in Section 3.1(a),
Section 3.1(b) and Section 3.1(c) an instrument executed by the chief financial officer of the Company and certifying that such financials were prepared in accordance with PRC GAAP, consistently
applied with prior practice for earlier periods (with the exception, for unaudited statements, such statements may be subject to normal year-end audit adjustments and exclude all footnotes required by
applicable accounting standard). As soon as practicable, but in any event within thirty (30) days after the end of each fiscal quarter, the Company shall also provide the Investors and the Board an analysis of results, highlighting notable
events and a thorough explanation of any material differences between actual figures, on the one hand and figures for the prior quarter and figures presented in the Budget on the other hand; 

 

	 	(f)	 such other information (A) provided to any other Shareholder, or (B) as an Investor or any assignee
of an Investor may from time to time reasonably request; 

  

	 	(g)	 if for any period the Company shall have any Subsidiary whose accounts are consolidated with those of the
Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated Subsidiaries; and

  

	 	(h)	 notwithstanding anything else in this Section 3.1 to the contrary, the Company may
cease providing the information set forth in this Section 3.1 during the period starting with the date sixty (60) days prior to the Company’s good faith estimate of the date of filing of, and ending on a date one
hundred eighty (180) days after the effective date of the registration effecting the IPO, to the extent required under the applicable rules of the jurisdiction in which the registration statement (or similar application for listing of the
Ordinary Shares) is to be filed; provided that the Company is actively employing its reasonable best efforts to cause such registration statement to become effective. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 4 

	3.2	 Inspection. 

So long as any Investor continues to hold no less than five percent (5%) of the total issued and outstanding Preferred Shares on an as
converted and as-exercised basis (as adjusted for any share splits, share dividends, recapitalizations or the like), the Company and any other Group Company shall permit the Investor to visit and inspect the
Company or any other Group Company’s properties, to examine its books of account and records and to discuss the Company or any other Group Company’s business, operations, conditions, affairs, finances and accounts with its directors,
officers, accountants and/or advisers, all at such reasonable times as may be reasonably requested by such Investor. 
  

	3.3	 U.S. Tax Matters. 

 

	 	(a)	 The Company will not take any action inconsistent with the treatment of the Company as a corporation for U.S.
federal income tax purposes and will not elect to be treated as an entity other than a corporation for U.S. federal income tax purposes. 

  

	 	(b)	 Upon request, the Company shall use reasonable efforts to assist each U.S. Investor in determining whether the
Company is a passive foreign investment company (“PFIC”) as defined in Section 1297 of the Internal Revenue Code of 1986, as amended (the “Code”) for any taxable year (and, if the U.S. Investor reasonably
believes that the Company was a PFIC for a taxable year, the status of each of the other Group Companies for such taxable year). For so long as a U.S. Investor holds 10% or more of the total voting power of the Company’s shares (a “10%
U.S. Investor”) the Company shall, upon request, use reasonable efforts to assist each 10% U.S. Investor in determining whether the Company is a controlled foreign corporation (“CFC”) as defined in Section 957 of the
Code for any taxable year. Following a determination by a U.S. Investor that it believes that the Company was a PFIC or a determination by a 10% U.S. Investor that it believes the Company was a CFC for a taxable year, the Company will, upon request,
use reasonable efforts to provide such U.S. Investor with information requested by the U.S. Investor that is reasonably available to the Company and necessary to permit such U.S. Investor to accurately prepare its U.S. federal income tax returns and
comply with U.S. federal income tax reporting requirements resulting from such determination. 

  

	 	(c)	 Any information obtained by a U.S. Investor under this Section 3.3 shall be kept
confidential except to the extent necessary in connection with the filing of U.S. federal income tax returns and compliance with U.S. federal income tax reporting requirements or proceedings with respect thereto. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 5 

	3.4	 Observer Rights. 

 

	 	(a)	 So long as any Investor, together with such Investor’s Affiliates, continues to hold no less than two
point five percent (2.5%) of the total issued and outstanding Shares (on an as-converted basis), but not represented in the Board, the Company shall invite, and shall cause any of the other Group Companies to
invite, a representative of each of such Investor (each an “Observer”) to, and such Observer shall have the right to, attend all meetings of the Board and all subcommittees of the Board and all meetings of the board and the similar
governing bodies of any other Group Companies and the committees and subcommittees of the foregoing, in a nonvoting observer capacity and, in this respect, shall give each Observer copies of all notices, minutes, consents, and other materials that
each Group Company provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that each Observer shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to
all information so provided. Notwithstanding the foregoing, so long as LAV, together with such its Affiliates, continues to hold any Shares, but not represented in the Board, LAV shall have the right to appoint an Observer. 

 

	 	(b)	 In the event that an Observer cannot or elect not to attend any meeting of the board, the committees and
subcommittees of the board, or the similar governing bodies of any Group Company, such Observer may by a written instrument appoint an alternate who need not be an Observer to attend such meeting. 

 

	3.5	 Termination of Information, Inspection and Observer Rights. 

The covenants set forth in Section 3.1, Section 3.2 and
Section 3.4 shall terminate and be of no further force or effect immediately upon the consummation of a Qualified IPO. 
  

	3.6	 Confidentiality. 

 

	 	(a)	 Disclosure of Terms. The terms and conditions of this Agreement, any term sheet or memorandum of
understanding entered into pursuant to the transactions contemplated hereby, all exhibits and schedules attached hereto and thereto, and the transactions contemplated hereby and thereby (collectively, the “Transaction Terms”),
including their existence, shall be considered Confidential Information and shall not be disclosed by any Party (including its respective shareholders and representatives) hereto to any third party except as permitted in accordance with the
provisions set forth below. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 6 

	 	(b)	 Permitted Disclosures. Notwithstanding the foregoing, the Company may disclose (i) the existence of
the investment to its bona fide prospective investors, employees, bankers, lenders, accountants, legal counsels and business partners, or to any person or entity to which disclosure is approved in writing by the Investors, such approval not to be
unreasonably withheld; and (ii) the Transaction Terms to its current shareholders, employees, bankers, lenders, accountants and legal counsels, in each case only where such persons or entities are under appropriate nondisclosure obligations
substantially similar to those set forth in this Section 3.6, or to any person or entity to which disclosure is approved in writing by the Investors, which such approval is not to be unreasonably withheld. The Investors may
disclose (i) the existence of the investment and the Transaction Terms to its Affiliate, such Investor/or its fund manager’s and/or its Affiliate’s legal counsel, fund manager, auditor, insurer, accountant, consultant or to an
officer, director, general partner, limited partner, its fund manager, shareholder, investment counsel or advisor, or employee of the Investor and/or its Affiliate (ii) any information for fund and inter-fund reporting purposes; (iii) any
information as required by law, Governmental Authorities, exchanges and/or regulatory bodies, including by the Securities and Exchange Commission (or equivalent for other venues); (iv) any information to bona fide prospective purchasers/investors of
any share, security or other interests in the Company; and (v) the fact of the investment to the public, in each case as it deems appropriate in its sole discretion. Any Party hereto may also provide disclosure in order to comply with
applicable Laws, as set forth in Section 3.6(c) below. 

  

	 	(c)	 Other than the existence of the investment and the Transaction Terms as provided in
Section 3.6(a) and Section 3.6(b) above, any other Confidential Information shall also not be disclosed by any of the Parties to any other Person, provided however, an Investor may disclose such
Confidential Information to: (i) such Investor/or its fund manager’s and/or its Affiliate’s legal counsel, fund manager, auditor, insurer, accountant, consultant on a
need-to-know basis, (ii) to any bona fide prospective purchasers/investors of any share, security or other interests in the Company as long as such prospective
investor agrees to be bound by the provisions of this Section 3.6, (iii) its Affiliate, an officer, director, general partner, limited partner, its fund manager, shareholder or Subsidiary of such Investor in the ordinary
course of business, (iv) any information for fund and inter-fund reporting purposes; or (v) as may otherwise be as required by Law, Governmental Authorities, exchanges and/or regulatory bodies, including by the Securities and Exchange
Commission (or equivalent for other venues); provided further that, the Company may disclose such Confidential Information to (i) its bona fide prospective investors, employees, bankers, lenders, accountants, legal counsels and business
partners on a need-to-know basis, or to any person or entity to the extent such disclosure is approved in writing by the Investors, and approval shall not to be
unreasonably withheld; and (ii) its current shareholders, employees, bankers, lenders, accountants and legal counsels, in each case only where such persons or entities are under appropriate nondisclosure obligations substantially similar to
those set forth in this Section 3.6, or to any person or entity to the extent such disclosure is approved in writing by the Investors, and such approval shall not to be unreasonably withheld. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 7 

	 	(d)	 Legally Compelled Disclosure. In the event that any Party is requested or becomes legally compelled
(including without limitation, pursuant to any applicable tax, securities, or other Laws and regulations of any jurisdiction) to disclose the Confidentiality Information as confirmed by advice from counsel, such party (the “Disclosing
Party”) shall, if and to the extent that it can lawfully do so, provide the other parties with prompt written notice of that fact and shall consult with the other parties regarding such disclosure. At the request of another party, the
Disclosing Party shall, to the extent reasonably possible and with the cooperation and reasonable efforts of the other parties, seek a protective order, confidential treatment or other appropriate remedy. In any event, the Disclosing Party shall
furnish only that portion of the information that is legally required and shall exercise reasonable efforts to obtain reliable assurance that confidential treatment will be accorded such information. 

 

	 	(e)	 Other Exceptions. Notwithstanding any other provision of this Section 3.6, the
confidentiality obligations of the Parties shall not apply to: (i) information which a restricted Party learns from a third party having the right to make the disclosure, provided the restricted Party complies with any restrictions imposed by
the third party; (ii) information which is rightfully in the restricted Party’s possession prior to the time of disclosure by the protected Party and not acquired by the restricted Party under a confidentiality obligation; or
(iii) information which enters the public domain without breach of confidentiality by the restricted Party. 

  

	 	(f)	 Press Releases, Etc. No announcements regarding the Investors’ investment in the Company may be
made by any Party hereto in any press conference, professional or trade publication, marketing materials or otherwise to the public without the prior written consent of the Investors and the Company, provided, that any such
announcement made by any partner, limited partner, bona fide potential partner or bona fide potential limited partner of the Investors shall not be subject to the consent of the Company. 

 

	 	(g)	 Other Information. The provisions of this Section 3.6 shall terminate and
supersede the provisions of any separate nondisclosure agreement executed by any of the Parties with respect to the transactions contemplated hereby. 

  

	4.	 RIGHT OF FIRST OFFER. 

 

	4.1	 Right of First Offer. 

Subject to the terms and conditions specified in this Section 4.1, and applicable securities laws, in the event the
Company proposes to offer, issue or sell any Additional Equity Securities, the Company shall first make an offering of such Additional Equity Securities to the Eligible Holders (the “Offerees”) and each Offeree shall have a
preemptive right to purchase a Pro Rata Share (as defined below) of all or any part of such Additional Equity Securities in accordance with the following provisions of this Section 4.1. Any Offeree shall be entitled to
apportion the right of first offer hereby granted it among themselves and their Affiliates in such proportions as it deems appropriate. 
  

	 	(a)	 The Company shall deliver a notice, in accordance with the provisions of Section 8.4
hereof (the “Offer Notice”) to the Offerees stating (i) its bona fide intention to issue such Additional Equity Securities, (ii) the number of such Additional Equity Securities to be issued, and (iii) the price and
terms, if any, upon which it proposes to issue such Additional Equity Securities. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 8 

	 	(b)	 Within twenty (20) calendar days after the receipt of the Offer Notice, each Offeree may, by written
notification, elect to purchase or obtain, in whole or in part, at the price and on the terms specified in the Offer Notice, up to that portion of such Additional Equity Securities which equals the proportion that the number of Ordinary Shares
(calculated on an as-converted basis assuming conversion of all convertible securities) then held, by such Offeree bears to the total number of Ordinary Shares (calculated on an
as-converted basis assuming conversion of all convertible securities), held by all Shareholders immediately prior to the issuance of Additional Equity Securities (the “Pro Rata Share”). For
avoidance of doubt, with respect to each Ordinary Shareholder holding Preferred Shares, any calculation in respect of its Pro Rata Shares shall be based on and shall be limited to the relevant Preferred Shares held by such Ordinary Shareholder,
without considering any Ordinary Shares held by such Ordinary Shareholder. 

  

	 	(c)	 The Company shall promptly, in writing, inform each Offeree that elects to purchase all of the Pro Rata Shares
available to it (each, a “Fully Exercising Holder”) of any other Offeree’s failure to do likewise. During the ten (10) day-period commencing immediately after receipt of such
information, each Fully Exercising Holder shall be entitled to notify the Company of its desire to purchase more than its Pro Rata Share of the Additional Equity Securities, stating the number of the Additional Equity Securities it proposes to
purchase. If as a result thereof, such oversubscription exceeds the total number of the remaining Additional Equity Securities available for purchase, the oversubscribing Fully Exercising Holder will be cut back by the Company with respect to their
oversubscriptions to that number of remaining Additional Equity Securities equal to the proportion that the number of Registrable Securities (calculated on an as-converted basis and exclusive of the Ordinary
Shares held by the Ordinary Shareholders) then held by such Fully Exercising Holder bears to the total number of Registrable Securities (calculated on an as-converted basis and exclusive of the Ordinary Shares
held by the Ordinary Shareholders) then held by all Fully Exercising Holders who wish to purchase such unsubscribed Additional Equity Securities. 

  

	 	(d)	 If all Additional Equity Securities referred to in the Offer Notice are not elected to be purchased or obtained
as provided in Section 4.1(b) and (c) hereof, the Company may, during the ninety (90)-day period following the expiration of the period provided in
Section 4.1(b) and (c) hereof, offer the remaining unsubscribed portion of such Additional Equity Securities to identified parties at a price not less than, and upon terms no more favorable to the Offerees than,
those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the Additional Equity Securities within such period, or if such agreement is not consummated within twenty (20) days of the execution thereof,
the right provided hereunder shall be deemed to be revived and such Additional Equity Securities shall not be offered unless first reoffered to the Offerees in accordance with this Section 4.1. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 9 

	4.2	 Termination. 

The provisions of Section 4 shall terminate upon the consummation of a Qualified IPO. 

 

	5.	 BOARD COMPOSITION AND VOTING MATTERS. 

 

	5.1	 Board Composition. 

Each Shareholder agrees to vote all of his, her or its Shares in the Company (whether now owned or hereafter acquired or which the Shareholder
may be empowered to vote), from time to time and at all times, in whatever manner shall be necessary to ensure that at each annual or special meeting of shareholders at which an election of directors is held or pursuant to any written consent of the
shareholders, the following persons shall be elected to the Board. 
  

	 	(a)	 HAN Yusheng (汉雨生) shall be entitled to elect two (2) directors of the Board (the
“Ordinary Directors”), initially to be HAN Yusheng (汉雨生), CHUAI Shaokun (揣少坤), provided that the chief executive officer shall be one of the Ordinary Directors. 

 

	 	(b)	 The Investors shall be entitled to elect up to six (6) directors of the Board (the
“Investors’ Directors”) in aggregate with the composition determined as follows: one (1) director shall be designated and appointed by LYFE (the “LYFE Director”), initially to be ZHAO
Jin (赵晋); one (1) director shall be designated and appointed by NLVC (the “NLVC Director”), initially to be DENG Feng (邓峰); one (1) director shall be designated and appointed by CTD, initially
to be LU Gang (陆刚); one (1) director shall be designated and appointed by Sequoia, initially to be YANG Yunxia (the “Sequoia Director”); one (1) director shall be shall be designated and appointed by
Evergreen, initially to be RONG Jing (戎璟) (the “Evergreen Director”); and (i) in the event that the GIC Warrant has not been exercised, so long as GIC holds no less than 4,259,800 Shares, as adjusted for any share
splits, share dividends, recapitalizations or the like, or (ii) in the event that the GIC Warrant has been exercised, so long as GIC holds no less than 5,324,750 Shares, as adjusted for any share splits, share dividends, recapitalizations or
the like, one (1) director shall be designated and appointed by GIC, initially to be Goh Chin Kiong (the “GIC Director”). 

  

	 	(c)	 Each Director of the Company shall have one (1) vote for each of the matters submitted to the Board of
Directors, except HAN Yusheng (汉雨生) shall have six (6) votes for each of the matters submitted to the Board of Directors. 

  

	5.2	 Size of the Board; Subsidiaries. 

Each Shareholder agrees to vote all of its Shares from time to time and at all times, in whatever manner shall be necessary to ensure that the
size of the Board shall be set at eight (8) directors. It is further agreed that upon the request from NLVC and/or LYFE and/or Sequoia and/or Evergreen and/or GIC, the board of directors of any other Group Company and, to the extent legally and
commercially feasible, other Subsidiaries of the Company (including in the event that the Company shall form or acquire any new Subsidiaries) shall have same board composition with the Company as determined in accordance with
Section 5.1, and the Company and the Key Holders shall procure that such nominee(s) are appointed to the relevant board of directors. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 10 

	5.3	 Removal of Board Members. 

Each Shareholder also agrees to vote all of his, her or its Shares from time to time and at all times in whatever manner as shall be necessary
to ensure that (i) no director elected pursuant to Section 5.1 of this Agreement may be removed from office unless (A) such removal is directed or approved by the person(s) or entity(ies) entitled under
Section 5.1 to designate or appoint that director or (B) the person(s) or entity(ies) originally entitled to designate or approve such director or occupy such Board seat pursuant to
Section 5.1 is no longer so entitled to designate or approve such director or occupy such Board seat for the reasons that: (x) the Company and the person(s) or entity(ies) entitled to designate or approve such director
or occupy such Board seat pursuant to Section 5.1 have mutually agreed in writing that such person(s) or entity(ies) shall no longer be entitled to designate or approve such director or occupy such Board seat; (y) such
person(s) or entity(ies) no longer hold(s) any shares in the Company; and/or (z) any other matters mutually agreed in writing by the Company and such person(s) or entity(ies) and (ii) any vacancies created by the resignation, removal or
death of a director elected pursuant to Section 5.1 shall be filled pursuant to the provisions of Section 5.1. 
  

	5.4	 All Shareholders agree to execute any written consents required to effectuate the obligations of this
Agreement, and the Company agrees at the request of any Shareholder entitled to designate directors to call a special meeting of shareholders for the purpose of electing directors. 

 

	5.5	 Increase in Authorized Share Capital. 

Each Shareholder agrees to vote all of its Shares from time to time and at all times, in whatever manner shall be necessary to authorize an
increase in the authorized share capital of the Company so that there will be sufficient Ordinary Shares available for conversion of all of the then-outstanding Preferred Shares at any time that an adjustment to the relevant conversion price with
respect to the Preferred Shares is made under the Articles. 
  

	5.6	 Specific Enforcement. 

Each Shareholder acknowledges and agrees that each Party hereto will be irreparably damaged in the event any of the provisions of this
Section 5 are not performed by the Shareholder in accordance with their specific terms or are otherwise breached. Accordingly, it is agreed that each of the Company and the Shareholders shall be entitled to an injunction to
prevent breaches of this Agreement and to specific enforcement of this Agreement and its terms and provisions in any action instituted in any court of competent jurisdiction, in addition to any other remedy to which the Parties may be entitled at
law or in equity. Each of the Parties to this Agreement hereby consents to personal jurisdiction in any such action brought in the courts of Hong Kong. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 11 

	5.7	 Term. 

The provisions of this Section 5 shall be effective as of the date hereof and shall continue in effect until and
shall terminate upon the consummation of a Qualified IPO. 
  

	6.	 RIGHT OF FIRST REFUSAL, CO-SALE AND RESTRICTIONS ON SALE.

  

	6.1	 Restrictions on Transfer. 

 

	 	(a)	 Transfer of Shares. 

Subject to Section 6.6, any proposed assignment, sale, offer to sell, pledge, mortgage, hypothecation, encumbrance,
disposition of or any other like transfer or encumbering, through one or a series of transactions, of any interest in any Shares now or hereafter owned or held by a Shareholder, either directly or indirect (in each case, a
“Transfer”) shall be made in compliance with the terms of this Section 6. For avoidance of doubt, the parties agree that the restrictions on the Transfer of the Shares held by the Ordinary Shareholder
contained in this Agreement shall apply to any indirect transfer and shall not be circumvented by means of any indirect transfer of the Shares, and any change in the equity interest of an Ordinary Shareholder that is an entity (including Holding
Entities), including without limitation as a result of (i) the issuance or redemption by such Ordinary Shareholder of any portion of its outstanding shares or equity, or (ii) a Transfer of such Ordinary Shareholder’s equity by its
equity holder, shall constitute a Transfer for purposes of this Agreement. 
  

	 	(b)	 Restriction on Transfer of the Ordinary Shares. 

 

	 	(i)	 So long as any Investor possesses any Equity Securities of the Company, the Founder shall not make any Transfer
regarding the Ordinary Shares directly and indirectly held by the Founder without the consent of the Investors, provided however, (a) the Founder in aggregate may Transfer no more than 2% of all outstanding and issued Shares of the Company for
each calendar year only with the prior written consent from at least three (3) Key Investors’ Directors; (b) the Founder in aggregation may Transfer more than 2% of all outstanding and issued Shares of the Company for each calendar
year only with the prior written consent from at least four (4) Key Investors’ Directors (including the consent of the GIC Director). For the avoidance of doubt, this Section 6.1(b)(i) shall not apply to any
Transfer regarding the Preferred Shares directly and indirectly held by the Founder. 

  

	 	(ii)	 Subject to Section 6.1(b)(i) above, without the prior written consent of at least one-half (1/2) of Key Investors’ Directors of the Company, the Ordinary Shareholders (except for the Founder who shall make a Transfer of his or her Ordinary Shares in accordance with subsection (i) above)
shall not effect any Transfer to any other party. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 12 

	 	(c)	 Right of First Offer on Sale of the Preferred Shares. 

 

	 	(i)	 Transfer Notice of the Preferred Shares. 

In the event that any of the Investors other than GIC (the “Preferred Shares Transferor”) receives a bona fide proposal for
purchase of Preferred Shares from any person (the “Preferred Shares Transferee”) (the “Proposed Sale”), then within five (5) calendar days of receipt of such offer from the Preferred Shares Transferee, the
Preferred Shares Transferor shall provide the Company and the Founder with written notice of the material terms of the Proposed Sale (the “Sale Notice”) which shall include the identity of the Preferred Shares Transferee and the
number and the share price of the transferred Preferred Shares (the “Transferred Preferred Shares”). 
  

	 	(ii)	 Right of First Offer for the Proposed Sale. 

The Company and the Founder (collectively, the “Qualified Purchasers”) shall have the right of first offer, to purchase any
or all of the Transferred Preferred Shares in whole or in part on the same terms and conditions as specified in the Sale Notice (the “Purchase Right”), provided that the Founder’ Purchase Right hereunder shall be subordinate to
the Company’s Purchase Right, and the Founder shall exercise such Purchase Right on pro rata basis. 
 Subject to the PRC Laws,
including without limitation to the SAFE rules and regulations, the Qualified Purchasers shall, within ten (10) calendar days of receipt of the Sale Notice (the “Purchase Right Exercise Period”) deliver an exercise notice to
the Preferred Shares Transferor to exercise its Purchase Right. If the Qualified Purchasers choose not to exercise or fully exercise its Purchase Right, or fail to exercise its Purchase Right within the Purchase Right Exercise Period, then the
Preferred Shares Transferor may sell the remaining Transferred Preferred Shares to a Preferred Shares Transferee on terms and conditions not more favorable than those specified in the Sale Notice. Thus, the Qualified Purchasers shall have no further
rights under this Section 6.1(c) with respect to the Proposed Sale. 
  

	 	(iii)	 Any Investor (except for GIC) shall not, without the prior written consent of HAN Yusheng
(汉雨生), transfer or dispose of any of its shares to an entity (the “Direct Competitor of the Company”) 1) the business operation and marketing of which in the PRC is to diagnose oncology genes for early cancer
diagnostic, cancer susceptibility, cancer monitoring and provide individualized medication guides for cancer patients by means of next generation gene sequencing (“NGS”); and 2) that directly competes with Group Companies in the PRC
by offering the same or substantially similar products or services that constitute the primary products or services offered by the Group Companies or Pipelines to be offered by the Group Companies. For the purpose of this Agreement, the term
“Pipelines” shall mean new products or services of the Group Companies which are to be launched within one (1) year from January 31, 2019. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 13 

	 	(iv)	 Unless otherwise expressly provided in this Section 6.1(c), the Investors are
entitled to transfer, sell, or otherwise dispose any of their Equity Securities in any manner without any limitation, subject to applicable Laws. Notwithstanding anything contained herein to the contrary, each of the Investors is entitled to
transfer, sell, or otherwise dispose any of its Equity Securities in any manner to any of its Affiliates. 

  

	 	(d)	 GIC’s Sale of the Preferred Shares. 

 

	 	(i)	 If GIC proposes to transfer any Shares of the Company to a third party other than its Affiliates, GIC shall
provide a list of the prospective transferees to the Company (“List of Transferees”). The Company shall, upon receipt of the List of Transferees, discuss in good faith with GIC and make suggestions to GIC for the purpose of
finalizing the List of Transferees. The final List of Transferees shall be subject to the mutual consent by GIC and the Company, provided that, the Company shall deliver its consent, objection or any proposed amendment (as the case may be) with
respect to the List of Transferees to GIC within five (5) Business Days following the receipt of the List of Transferees. 

  

	 	(ii)	 Notwithstanding anything to the contrary, Section 6.1(d)(i) shall not apply to
(x) a sale pursuant to Section 6.3, or (y) a sale in the event that the Company fails to fulfill its redemption obligations or pay on the date that the related redemption payment were due pursuant to the Articles.

  

	 	(iii)	 Subject to the Section 6.1(d)(i), GIC is entitled to Transfer any of the Equity
Securities in the Company in any manner without any limitation, subject to applicable Laws. Notwithstanding anything contained herein to the contrary, GIC is entitled to Transfer any of the Equity Securities in the Company in any manner to any of
its Affiliates. 

  

	 	(iv)	 For the avoidance of doubt, Section 6.1(c) shall not apply to GIC or its Affiliates
in any event. 

  

	6.2	 Right of First Refusal 

 

	 	(a)	 Proposed Transfer Notice. 

Each Ordinary Shareholder (including its successors and permitted assigns) (a “Transferor”) proposing to make a Transfer (a
“Proposed Transfer”) must deliver a notice (the “Proposed Transfer Notice”) to the Company and the Eligible Holders. Such Proposed Transfer Notice shall contain the material terms and conditions of the Proposed
Transfer, including without limitation a description and the share price of the Shares (the “Transfer Shares”) that such Transferor may propose to transfer, and the identity of the Prospective Transferee. In the event of a conflict
between this Agreement and any other agreement that may have been entered into by a Transferor with the Company that contains a preexisting right of first refusal, the terms of this Agreement shall prevail and the preexisting right of first refusal
shall be deemed satisfied by compliance with this Section 6.2. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 14 

	 	(b)	 Grant of Right of First Refusal to the Eligible Holders. 

 

	 	(i)	 Each Eligible Holder shall have the right for a period of twenty-one
(21) days (the “Eligible Holders’ ROFR Exercise Period”) following the Eligible Holders’ receipt of the Proposed Transfer Notice to elect to purchase its respective pro rata share of the Transfer Share at the same
price and subject to the same material terms and conditions as described in the Proposed Transfer Notice (the “Right of First Refusal”). 

  

	 	(ii)	 Each Eligible Holder may exercise such right of first refusal and, thereby, purchase all or any portion of its
pro rata share of the Transfer Share, by notifying the Transferor and the Company in writing, before expiration of the Eligible Holders’ ROFR Exercise Period as to the number of such Transfer Share that it wishes to purchase.

  

	 	(iii)	 Each Eligible Holder’s pro rata share of the Transfer Share shall be a fraction, the numerator of which
shall be the total number of the Shares and other Equity Securities of the Company (calculated on an as converted but otherwise non-diluted basis) owned by such Eligible Holder on the date of the Proposed
Transfer Notice and the denominator of which shall be the total number of the Shares and other Equity Securities of the Company (calculated on an as-converted but otherwise
non-diluted basis) held by all the Eligible Holders on such date (the “ROFR Pro Rata Share”). For the avoidance of doubt, with respect to each Ordinary Shareholder holding Preferred Shares,
any calculation in respect of its ROFR Pro Rata Share shall be based on and shall be limited to the relevant Preferred Shares held by such Ordinary Shareholder, without considering any Ordinary Shares held by such Ordinary Shareholder.

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 15 

	 	(iv)	 If any Eligible Holder elects not to exercise or fully exercise or fails to fully exercise such right of first
refusal pursuant to Section 6.2(b)(ii), the Transferor shall, within five (5) days following the receipt of all the Eligible Holders’ written notices pursuant to Section 6.2(b)(ii) or the
expiration of the Eligible Holders’ ROFR Exercise Period (whichever is earlier), give notice of such election or failure (the “Re-allotment Notice”) to each other Eligible Holders that
elected to purchase its entire pro rata share of the Transfer Share (the “Purchasing Holders”), which notice shall set forth the number of the Transfer Share not purchased by the other Eligible Holders pursuant to
Section 6.2(b)(ii) (such shares, the “Remaining Transfer Share”). The Purchasing Holders shall have a right of re-allotment such that they shall have fifteen
(15) days from the date such Re-allotment Notice was given to elect to increase the number of the Transfer Share they agreed to purchase under Section 6.2(b)(ii). Such right of re-allotment shall be subject to the following conditions: each Purchasing Holder shall first notify the Transferor of its desire to increase the number of the Transfer Share it agreed to purchase under
Section 6.2(b)(ii), stating the number of the additional Transfer Share it proposes to buy (the “Additional Transfer Share”). If, as a result thereof, the total number of Additional Transfer Share the
Purchasing Holders propose to buy exceeds the total number of the Remaining Transfer Share, the Remaining Transfer Share shall be allocated as necessary such that each Purchasing Holder electing to purchase the Additional Transfer Share (an
“Over-Purchasing Holder”) shall have the right to purchase such number of Additional Transfer Share equal to the product obtained by multiplying (i) the number of the Remaining Transfer Share by (ii) a
fraction, the numerator of which is the number of the Registrable Securities (calculated on an as-converted but otherwise non-diluted basis and exclusive of the Ordinary
Shares held by the Ordinary Shareholder ) held by such Over-Purchasing Holder and the denominator of which is the total number of Registrable Securities (calculated on an as-converted but otherwise non-diluted basis and exclusive of the Ordinary Shares held by the Ordinary Shareholder) held by all Over-Purchasing Holders, provided that in no event shall an Over-Purchasing Holder be obligated to purchase
more than the maximum number of Additional Transfer Share specified in such Over-Purchasing Holder’s written notice. The procedures described in the preceding sentence shall be repeated until the earlier to occur if (i) there are no
Remaining Transfer Share or (ii) the Over-Purchasing Holders do not wish to purchase any additional Remaining Transfer Share. 

  

	 	(v)	 Subject to applicable securities Laws, the Eligible Holders shall be entitled to apportion the Transfer Share
to be purchased among its partners and/or Affiliates upon written notice to the Company and the Transferor. 

  

	 	(vi)	 If an Eligible Holders gives the Transferor notice that it desires to purchase the Transfer Share, then payment
for the Transfer Share to be purchased shall be made by wire transfer in immediately available funds of the appropriate currency, against allotment of such Transfer Share together with an executed instrument of transfer to be purchased at a place
agreed by the Transferor and all the participating Eligible Holders and at the time of the scheduled closing therefor, which shall be no later than forty-five (45) days after the Eligible Holders’ receipt of the Proposed Transfer Notice.

  

	 	(c)	 Notwithstanding the foregoing, in the event that any Ordinary Shareholder (including its successors and
permitted assigns) proposed to make a Proposed Transfer in relation to any Ordinary Share of the Company: 

  

	 	(i)	 The Company shall have the right, prior to any Eligible Holders’ exercise of Right of First Refusal, for a
period of fifteen (15) days (the “Company’s ROFR Exercise Period”) following the receipt of the Proposed Transfer Notice to elect to purchase any or all of such Transfer Shares at the same price and subject to the same
material terms and conditions as described in the Proposed Transfer Notice. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 16 

	 	(ii)	 The Company may exercise such right and, thereby, purchase any or all of such Transfer Shares, by notifying the
Transferor in writing, before expiration of the Company’s ROFR Exercise Period, that it wishes to purchase any or all of such Transfer Shares. 

  

	 	(iii)	 If the Company gives the Transferor notice that it desires to purchase any or all such Transfer Shares, then
payment for such Transfer Shares shall be made by check or wire transfer in immediately available funds of the appropriate currency, against allotment of such Transfer Shares at a place agreed by the Transferor and the Company and at the time of the
scheduled closing therefor, which shall be no later than forty-five (45) days after the Company’s receipt of the Proposed Transfer Notice. 

  

	 	(iv)	 Regardless of any other provision of this Agreement, if the Company declines in writing or fails to exercise or
fully exercise its right of first refusal pursuant to this Section 6.2(c) with respect to such Transfer Shares, then the Transferor shall be under no obligation to transfer the remaining Transfer Shares to the Company
pursuant to this Section 6.2(c) and shall then be required to provide another notice regarding the remaining Transfer Shares which are not purchased by the Company to each Eligible Holder (the “Additional Proposed
Transfer Notice”, together with the Proposed Transfer Notice, the “Transfer Notice”) (which shall contain the same conditions and price for sale of the remaining Transfer Shares as set forth in the Proposed Transfer Notice)
within five (5) days, then each Eligible Holder shall have the right, within the Eligible Holders’ ROFR Exercise Period following the Eligible Holders’ receipt of the Additional Proposed Transfer Notice, to elect to purchase its
respective pro rata share of the Transfer Share at the same price and subject to the same material terms and conditions as described in the Proposed Transfer Notice, and the provisions set forth in this Section 6 shall
apply to Eligible Holder’s exercise of Right of First Refusal mutatis mutandis. 

  

	 	(v)	 For the avoidance of doubt, the Company shall not have any Right of First Refusal in relation to the Ordinary
Shareholder’s Transfer of any Preferred Shares or any shares converted therefrom, in which case Section 6.2 (b) shall apply to such Transfer. 

 

	 	(d)	 Purchase Price. The purchase price for the Transfer Share to be purchased by the Company or the Eligible
Holders exercising their right of first refusal will be the price set forth in the Transfer Notice. If the purchase price in the Transfer Notice includes consideration other than cash, the cash equivalent value of the non-cash consideration will be
as previously determined by the Board (including the affirmative vote of at least one-half (1/2) of Key Investors’ Directors). 

 

	 	(e)	 Rights of Transferor. If the Company or any Eligible Holders exercises its right of first refusal to
purchase the Transfer Share, then, upon the date the notice of such exercise is given by the Company or such Eligible Holders, the Transferor will have no further rights as a holder of such Transfer Share except the right to receive payment for such
Transfer Share from the Company or the Eligible Holders in accordance with the terms of this Agreement, and the Transferor will forthwith cause all certificate(s) evidencing such Transfer Share to be surrendered to the Company or the Eligible
Holders for transfer to the Company or the Eligible Holders, as applicable together with an executed instrument of transfer. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 17 

	 	(f)	 Application of Co-Sale Right. Regardless of any other provision of this Agreement, if any
Eligible Holders declines in writing or fails to exercise its right of first refusal and if there are any Remaining Transfer Share following the procedures provided in Section 6.2(b) and/or
Section 6.2(c), then the Transferor shall give each Eligible Holder a written notice (the “First Refusal Expiration Notice”) specifying that the Eligible Holders have not exercised their right of first
refusal in full and that the Remaining Transfer Share not purchased by the Company and any Eligible Holders pursuant to Section 6.2(b) and/or Section 6.2(c) (the “Unsold Transfer
Share”) shall be subject to the co-sale right of the Co-Sale Holder (as defined in Section 6.3 below) described in
Section 6.3 below, in which case the First Refusal Expiration Notice shall specify (i) the number of the Unsold Transfer Share, (ii) the Co-Sale Pro Rata Portion (as defined
in Section 6.3 below) of the Unsold Transfer Share for the purpose of such co-sale right and (iii) the name of the Co-Sale Eligible
Holder(s) (as defined in Section 6.3 below). For avoidance of any doubt, the co-sale right under Section 6.3 shall not apply to any Eligible Holders that has
successfully purchased any Transfer Share as a result of its exercise of the right of first refusal pursuant to Section 6.2(b). 

  

	6.3	 Right of Co-Sale. 

 

	 	(a)	 If any Transfer Shares subject to a Proposed Transfer are not purchased pursuant to
Section 6.2 above and thereafter are to be sold to a Prospective Transferee (such Transfer Shares, the “Co-Sale Eligible Shares”), each Eligible Holder that has not
exercised its rights under Section 6.2(b) (each an “Co-Sale Eligible Holder”) may elect to exercise its Right of Co-Sale and
participate on a pro-rata basis in the Proposed Transfer on the same terms and conditions specified in the Proposed Transfer Notice. To exercise its Right of Co-Sale,
the Co-Sale Eligible Holder must give the Transferor written notice to that effect within fifteen (15) calendar days (the “Co-Sale Period”) after
the expiration of the Eligible Holders’ ROFR Exercise Period as provided in Section 6.2(b), and upon giving such notice the Co-Sale Eligible Holder shall be deemed to have
effectively exercised the Right of Co-Sale. 

  

	 	(b)	 Each Co-Sale Eligible Holder, by timely exercising its Right of Co-Sale by delivering the written notice provided for above in Section 6.3(a) may include in the Proposed Transfer all or any part of its Shares equal to the product (the “Co-Sale Pro Rata Portion”) obtained by multiplying (i) the aggregate number of Co-Sale Eligible Shares by (ii) a fraction, the numerator of which is the
number of Ordinary Shares owned by such Co-Sale Eligible Holder (calculated on an as-converted basis assuming conversion of all convertible securities) immediately
before consummation of the Proposed Transfer and the denominator of which is the total number of Ordinary Shares owned, in the aggregate, by all Co-Sale Eligible Holders (calculated on an as-converted basis assuming conversion of all convertible securities) immediately prior to the consummation of the Proposed Transfer, plus the number of Ordinary Shares held by the Transferor (calculated on an as-converted basis assuming conversion of all convertible securities). To the extent that one or more of the Co-Sale Eligible Holders exercises such right of participation in
accordance with the terms and conditions set forth herein, the number of Co-Sale Eligible Shares that the Transferor may sell in the Proposed Transfer shall be correspondingly reduced. For the avoidance of
doubt, with respect to each Ordinary Shareholder holding Preferred Shares, any calculation in respect of its Co-Sale Pro Rata Portion shall be based on and shall be limited to the relevant Preferred Shares
held by such Ordinary Shareholder, without considering any Ordinary Shares held by such Ordinary Shareholder. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 18 

	 	(c)	 The sale of the Co-Sale Eligible Shares and remaining Transfer Shares
shall occur within twenty-five (25) calendar days from the beginning of the Co–Sale Period (the “Co-Sale Closing”). For avoidance of doubt, the Right of Co–Sale shall not apply
with respect to Transfer Shares sold or to be sold to the Eligible Holders under the Right of First Refusal in Section 6.2. 

  

	 	(d)	 A Co-Sale Eligible Holder shall effect its participation in the
Proposed Transfer by delivering to the Transferor, prior to the Co-Sale Closing, one or more share certificates, together with an executed instrument of transfer to the Prospective Transferee, representing:

  

	 	(i)	 the number of Ordinary Shares that such Eligible Holder elects to include in the Proposed Transfer; or

  

	 	(ii)	 the number of Preferred Shares that are at such time convertible into the number of Ordinary Shares that such
Eligible Holder elects to include in the Proposed Transfer; provided, however, that if the Prospective Transferee objects to the allotment of convertible Preferred Shares in lieu of Ordinary Shares, such Eligible Holder shall first
convert the Preferred Shares into Ordinary Shares and allot Ordinary Shares as provided above. The Company agrees to make any such conversion concurrent with and contingent upon the actual transfer of such shares to the Prospective Transferee.

  

	 	(e)	 The terms and conditions of any sale pursuant to this Section 6.3 will be contained
in, and governed by, a written purchase and sale agreement with customary terms and provisions for such a transaction. 

  

	 	(f)	 Each share certificate a Co-Sale Eligible Holder delivers to the
Transferor pursuant to Section 6.3(d) above will be transferred to the Prospective Transferee against payment therefor and the register of members of the Company shall be updated in consummation of the sale of the Transfer
Shares pursuant to the terms and conditions specified in the Proposed Transfer Notice and the purchase and sale agreement, and the Transferor shall concurrently therewith remit to each Co-Sale Eligible Holder
the portion of the sale proceeds to which such Co-Sale Eligible Holder is entitled by reason of its participation in such sale. If any Prospective Transferee(s) refuse(s) to purchase securities subject to the
Right of Co-Sale from any Co-Sale Eligible Holder exercising its Right of Co-Sale hereunder, no Transferor may sell any Transfer
Shares to such Prospective Transferee(s) unless and until, simultaneously with such sale, such Transferor purchases all securities subject to the Right of Co-Sale from such
Co-Sale Eligible Holder. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 19 

	6.4	 Proposed Transfer - Compliance Period. 

If any Proposed Transfer is not consummated within ninety days (90) days after receipt of the Proposed Transfer Notice by the Company and
the Eligible Holders, the Transferor proposing to make a Proposed Transfer may not sell any Transfer Shares unless such Transferor has complied in full with each provision of this Section 6. The exercise or election not to
exercise any right by any Eligible Holder hereunder shall not adversely affect its right to participate in any other sales of Transfer Shares subject to this Section 6. 

 

	6.5	 Effect of Failure to Comply. 

 

	 	(a)	 Any Proposed Transfer not made in compliance with the requirements of this Agreement (including without
limitation this Section 6) shall be null and void ab initio, shall not be recorded on the books or register of the Company or its transfer agent and shall not be recognized by the Company. Each Party hereto
acknowledges and agrees that any breach of this Agreement would result in substantial harm to the other Parties hereto for which monetary damages alone could not adequately compensate. Therefore, the Parties hereto unconditionally and irrevocably
agree that any non-breaching Party hereto shall be entitled to seek protective orders, injunctive relief and other remedies available at law or in equity (including, without limitation, seeking specific
performance or the rescission of purchases, sales and other transfers of Shares not made in strict compliance with this Agreement). 

  

	 	(b)	 If any Ordinary Shareholder becomes obligated to sell any Shares to the Company under this Agreement and fails
to allot such Shares in accordance with the terms of this Agreement, the Company may, at its option, in addition to all other remedies it may have, send to such Ordinary Shareholder the purchase price for such Shares as is herein specified and
cancel on its books or registers of members the certificate of certificates representing the shares to be sold. 

  

	 	(c)	 If any Ordinary Shareholder purports to sell any Shares in contravention of the Right of Co-Sale (a “Prohibited Transfer”), each Eligible Holder, in addition to such remedies as may be available by Laws, in equity or hereunder, is entitled to require such Transferor to purchase Shares
from the Eligible Holder, as provided below, and such Transferor will be bound by the terms of such option. If a Transferor makes a Prohibited Transfer, each Eligible Holder upon timely exercise of its Right of
Co-Sale under Section 6.3 may require such Transferor to purchase from such Eligible Holder the type and number of Shares that such Eligible Holder would have been entitled to sell to
the Prospective Transferee under Section 6.3 had the Prohibited Transfer been effected pursuant to and in compliance with the terms of Section 6.3. The sale will be made on the same terms and
subject to the same conditions as would have applied had the Transferor not made the Prohibited Transfer, except that the sale (including, without limitation, the delivery of the purchase price) must be made within ninety (90) days after the
Eligible Holder learns of the Prohibited Transfer, as opposed to the timeframe prescribed in Section 6.3. Such Transferor shall also reimburse such Eligible Holder for any and all fees and expenses, including legal fees and
expenses, incurred pursuant to the exercise or the attempted exercise of such Investor’s Right of Co-sale under Section 6.3. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 20 

	6.6	 Exempted Transfers. 

 

	 	(a)	 Notwithstanding the foregoing or anything to the contrary herein, the provisions of
Section 6.2 and Section 6.3 shall not apply: (i) to a repurchase of Shares from a Transferor by the Company at a price no greater than that originally paid by such Transferor for such Shares
and pursuant to an agreement containing vesting and/or repurchase provisions approved by the Board, (ii) in the case of a Transferor that is a natural person, upon a transfer of Shares by such Transferor, either during his or her lifetime or on
death by will or intestacy, to his or her Immediate Family Members or any other relatives approved by the Board (including the affirmative votes of 1/2 Key Investors’ Directors), or any custodian or trustee for the account of a Transferor or a
Transferor’s Immediate Family Members, (iii) any transfer of shares of the Company indirectly held by any Key Holder from the Holding Entity to such Key Holder at cost, or (iv) the sale of any Shares to the public in a Qualified IPO,
provided that (a) adequate documentation therefor is provided to the Investors and that any such Permitted Transferee agrees in writing to be bound by this Agreement in place of the relevant transferor by executing an Adherence Agreement
substantially in the form attached hereto as Exhibit A (“Adherence Agreement”); and (b) such Transfer is effected in compliance with all applicable Laws including, without limitation, Circular 37 provided however,
without prejudice to the compliance with other applicable Laws, the Transfer of Shares to any custodian or trustee for the account of (x) a Transferor, (y) a Transferor’s Immediate Family Members or (z) a Transferor’s other
relatives approved by the Board (including the affirmative votes of 1/2 Key Investors’ Directors), as set out in sub-section (ii) above, shall be effected in compliance with Circular 37 only to the
extent legally practicable; provided, further, such transferor shall remain liable for any breach by such Permitted Transferee of any provision hereunder. 

 

	 	(b)	 In the event that the Company is to alter or dissolve the existing Captive Structure, each of the Investors,
severally but not jointly, shall be entitled to transfer any and all Equity Securities in the Company then held by the Investors respectively to an Affiliate, Affiliate Fund or a third party designated by the Investors respectively (each as an
“Investor’s Designated Party”) at a price solely decided by the Investors respectively, or swap its Equity Securities in the Company with new Equity Securities denominated in RMB to be issued by any of the surviving Group
Companies to Investor’s Designated Party. As a result, the Investor’s Designated Party shall hold an equity interest in the surviving Group Companies equivalent to the Equity Securities then held by the Investors respectively in the
Company. The Parties shall vote, and cause their respective directors or representatives to vote in favor of such share transfer, and cause the Company and the Group Companies to take all necessary actions to obtain consents and approvals from
competent agencies, if any, to make registration of the share transfer, and to issue new shares, if applicable. If there is any tax or charge arising from such transfer and/or swap of Equity Securities, the Parties shall consult in good faith to
work out an amicable solution. Notwithstanding the foregoing or anything to the contrary herein, the provisions of Sections 6.1, 6.2, 6.3, 6.4 and 6.5 shall not apply in the case of a transfer or swap in accordance
with this Section 6.6(b). 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 21 

	6.7	 Assignment. Notwithstanding anything herein to the contrary: 

 

	 	(a)	 Assignment and Transfer. The terms and conditions of this Agreement shall inure to the benefit of and be
binding on the respective transferees, successors and/or assigns of the parties hereto. This Agreement is not assignable except in connection with a Transfer of Shares of the Company by a Shareholder in accordance with this Agreement but only to the
extent of such Transfer, provided that (i) any such transferee shall execute and deliver to the Company and the other parties hereto the Adherence Agreement as provided in Section 6.6(a), and (ii) the
Company is given a written notice at the time of such assignment stating the name and address of the assignee, provided further that any right of any Investor under this Agreement are fully assignable to its Affiliates and Affiliates Fund without
the consent of the other parties hereto. 

  

	 	(b)	 Adherence Agreement. For any transfer of Shares to be deemed effective, the transferee shall assume the
obligations of the transferor under this Agreement by executing and delivering to the Company an Adherence Agreement. Upon the execution and delivery of an Adherence Agreement by any transferee, such transferee shall be deemed to be an Ordinary
Shareholder, Investor, Founder or Key Holder hereunder, as appropriate. 

  

	6.8	 Term. 

The provisions of this Section 6 shall terminate upon the consummation of a Qualified IPO. 

 

	7.	 ADDITIONAL COVENANTS.  

 

	7.1	 Protective Provisions. 

 

	 	(a)	 Matters Requiring the Approval of the Investors. 

In addition to any other vote or consent required elsewhere in this Agreement, the Articles or by any applicable statute, each of the Company
and any other Group Companies hereby covenants and agrees with the Investors that it shall not and the Key Holders shall procure that each Group Company does not, either directly or indirectly, by amendment, waiver, merger, consolidation, scheme of
arrangement, amalgamation or otherwise, take, permit to occur, approve, authorize or agree or commit to do (substituting references to “Company” with “Group Company” in the provisions and defined terms below as the context
requires) any of the following actions (whether in a single transaction or a series of related transactions) without the prior affirmative approval or consent of the Majority Preferred Shares Holders. In relation to
Section 7.1(a), where any act listed in clauses (i) through (xiv) below requires a Special Resolution of the Members as defined in the Articles where a general meeting of Members is convened and the consent referred to
above is not obtained, each holder of the Preferred Shares who votes against the resolution shall be deemed to have ten (10) times the number of votes of all members who vote for the resolution: 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 22 

	 	(i)	 any increase in the authorized number of Preferred Shares except for any Equity Securities issued or issuable
pursuant to the Transaction Documents; any amendment or change of the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, any Preferred Shares; 

 

	 	(ii)	 any action that authorizes, creates, issues, increases or decreases the authorized number of the Equity
Securities, except for (i) the Ordinary Shares issuable upon conversion of Preferred Shares (ii) any Equity Securities issued or issuable pursuant to the Transaction Documents; and (iii) any Equity Securities issued under the option
plan with the approval of the Board (including one-half (1/2) of the Key Investors’ Directors); 

  

	 	(iii)	 any authorization, designation or issuance, whether by reclassification or otherwise, of any new class or
series of shares or any other securities convertible into Equity Securities of the Company ranking on a parity with or senior to the Preferred Shares in any preference or priority such as right of redemption, liquidation preference, voting or
dividends or any increase in the authorized or designated number of any such new class or series, except for any Equity Securities issued or issuable pursuant to the Transaction Documents; 

 

	 	(iv)	 any purchase, repurchase, redemption or retirement of any Equity Securities (excluding shares repurchased upon
termination of an employee or consultant pursuant to a restricted share purchase agreement or employee incentive plan); 

  

	 	(v)	 any amendment or modification, alteration, repeal to or waiver of any provision of any of the memorandum or
articles or similar organizational documents or by-laws of the Group Companies or any other constitutional documents, including, without limitation, by operation of a merger, consolidation, reorganization or
similar transaction; 

  

	 	(vi)	 the commencement of or consent to any proceeding seeking (i) to adjudicate it as bankrupt or insolvent,
(ii) liquidation, winding up, dissolution, reorganization, or other arrangement under law relating to bankruptcy, insolvency or reorganization or relief of debtors, including but without limitation, the Deemed Liquidation Event, or
(iii) the entry of an order for relief or the appointment of a receiver, trustee, or other similar official for it or for any substantial part of its property; 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 23 

	 	(vii)	 any agreement by the Group Companies regarding selling, transferring, licensing, changing, encumbering or
otherwise disposing of any trademarks, patents, know-how or other intellectual property owned by the Group Companies; 

  

	 	(viii)	 any reclassification or recapitalization of the outstanding capital shares of any Group Company;

  

	 	(ix)	 the selection of the listing exchange for any public offering of any securities of a Group Company (including a
Qualified IPO) or approve the valuation and terms and conditions for such public offering; 

  

	 	(x)	 any change of authorized size of the Board or change the manner in which any director on the Board is appointed
(other than change of director by the shareholder who appoints him or her); 

  

	 	(xi)	 changing the name of any Group Company, or ceasing any business undertaking of any Group Company substantially
as then currently conducted by such Group Company, change of any material part of its then current business or enter into business that is outside of its then current business; 

 

	 	(xii)	 any adoption or change of the terms of any bonus or profit sharing scheme or any employee share option or share
participation schemes or similar plans; 

  

	 	(xiii)	 any Trade Sale or Loss of Control; or 

 

	 	(xiv)	 any action by a Group Company to authorize, approve or enter into any agreement or obligation with respect to
any of the actions listed above. 

  

	 	(b)	 Matters Requiring the Approval of Board. 

In addition to any other vote or consent required elsewhere in this Agreement, the Articles or by any applicable statute, each of the Company
and any other Group Companies hereby covenants and agrees that it shall not and the Key Holders shall procure that each Group Company does not, either directly or indirectly, by amendment, waiver, merger, consolidation, scheme of arrangement,
amalgamation or otherwise, take, permit to occur, approve, authorize or agree or commit to do (substituting references to “Company” with “Group Company” in the provisions and defined terms below as the context requires) any of
the following actions (whether in a single transaction or a series of related transactions) without the prior affirmative approval or consent of a simple majority of the votes of the Board (including the affirmative vote of at least one-half (1/2) of all the Key Investors’ Directors acting in his or her capacity as a director of the Company and as a representative of the Investor(s)): 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 24 

	 	(i)	 appointing, terminating or determining the compensation of the chairman, chief executive officer, president,
general manager, Financial Controller, chief operation officer, chief technology officer, vice president-level or above; 

  

	 	(ii)	 issuing options or administrating the Company’s share plan or any other equity incentive, purchase or
participation plan for the benefit of employees; 

  

	 	(iii)	 creating, allowing to arise or issuing any debenture constituting a pledge, lien, or charge on all or any of
the assets or rights of any Group Company; 

  

	 	(iv)	 establishment of any new direct or indirect subsidiary by any Group Company; 

 

	 	(v)	 approving and amending annual budget and business plan of any Group Company; 

 

	 	(vi)	 acquiring any investment or incurring any commitment in excess of US$300,000 at any time in respect of any one
transaction, or in respect of a series of related transactions within a fiscal year, by any Group Company; 

  

	 	(vii)	 amending the accounting or financial policies or changing the financial year of any Group Company;

  

	 	(viii)	 any transaction between or among the Group Companies and with any Related Party or member of such Related
Party’s family; 

  

	 	(ix)	 incurring any indebtedness or assuming any financial obligation or issuing, assuming, guaranteeing or creating
any liability for borrowed money in excess of US$3,000,000 in a single transaction, or in a series of related transactions within a fiscal year, unless such liability is incurred pursuant to the then current business plan or annual budget;

  

	 	(x)	 purchase or disposal of business/assets in excess of US$3,000,000 in a single transaction, or in a series of
related transactions within a fiscal year, other than the purchase or disposal of business/assets in the ordinary course of business; 

  

	 	(xi)	 extension of any loan or guarantee for indebtedness in excess of US$300,000 to any third party in a single
transaction, or in a series of related transactions within a fiscal year; 

  

	 	(xii)	 equity investment in any third party in excess of US$1,500,000 in a single transaction, or in a series of
related transactions within a fiscal year; 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 25 

	 	(xiii)	 any single transaction, or a series of related transactions within a fiscal year, that is or are outside
ordinary course of business and involving an amount in excess of US$1,500,000 or exclusive relationship; 

  

	 	(xiv)	 initiating or settling any single material litigation or arbitration involving an amount in excess of
US$1,500,000; 

  

	 	(xv)	 appointing or changing the auditors of any Group Company; 

 

	 	(xvi)	 any action that results in the payment or declaration of a dividend on any shares of the Ordinary Shares or the
Preferred Shares; 

  

	 	(xvii)	 any action that might cause harm to, or result in an alternation, dissolution, cancellation or termination of
the existing Captive Structure, including but not limited to any attempt to convert the Company into a domestic company under the PRC Laws; or 

  

	 	(xviii)	 any action by a Group Company to authorize, approve or enter into any agreement or obligation with respect to
any of the actions listed above. 

  

	 	(c)	 Matters Requiring the Approval of Majority Series C Preferred Shares Holders. 

In addition to any other vote or consent required elsewhere in this Agreement, the Articles or by any applicable statute, each of the Company
and any other Group Companies hereby covenants and agrees with the Investors that it shall not and the Key Holders shall procure that each Group Company does not, either directly or indirectly, by amendment, waiver, merger, consolidation, scheme of
arrangement, amalgamation or otherwise, take, permit to occur, approve, authorize or agree or commit to do (substituting references to “Company” with “Group Company” in the provisions and defined terms below as the context
requires) any of the following actions (whether in a single transaction or a series of related transactions) without the prior affirmative approval or consent of the Majority Series C Preferred Shares Holders: 

 

	 	(i)	 create or designate (including by reclassification of existing shares), or authorize any issuance of any
additional Equity Securities (including, but not limited to, all classes of shares, warrants, rights to subscribe for shares and securities convertible into any share class) for a consideration per share that is lower than the subscription price of
the Series C Preferred Shares, except for the transfer of existing Shares of the Company and the issuance of any Shares of the Company in connection with (i) employees stock option plan of the Company; (ii) any share split, share dividend,
combination, recapitalization or other similar transaction of the Company; (iii) the conversion of the outstanding Preferred Shares of the Company into the Ordinary Shares of the Company; and (iv) any Equity Securities issued or issuable
pursuant to the Transaction Documents; 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 26 

	 	(ii)	 any transaction or series of related transactions by the Company, (i) which shall constitute a change of
control event (including the sale or exclusive licensing of substantially all of the intellectual property assets of the Group to a third party), or in which the relevant Group Company or its shareholders immediately prior to such transaction shall
not, as a result of or subsequent to the transaction, hold a majority of the voting power or share capital of the surviving or resulting entity with an implied pre-money valuation of the Company with per share
price less than the per share issue price with respect to the series C round of financing of Company (subject to adjustment any share dividend, share split, combination of shares, reorganization, recapitalization, reclassification or other similar
event affecting such shares); 

  

	 	(iii)	 any waiver or amendment, alternation or modification to the provision related to a price based anti-dilution
adjustment applicable to the Series C Preferred Shares or Series C+ Preferred Shares; 

  

	 	(iv)	 any initial public offering of any equity securities of the Company, which is not a Qualified IPO;

  

	 	(v)	 any waiver of the treatment of an event as a liquidation event or deemed liquidation event or some similar
concepts under the current effective investment and constitutional documents of the Company, provided however, in the event where a liquidation event or deemed liquidation event or some similar concepts occurs and the implied pre-money valuation of the Company is no less than US$1,442,496,338, the waiver of application of liquidation preference waterfall as set out in memorandum and articles of association of the Company doesn’t
require the consent of Majority Series C Preferred Shares Holders. 

  

	 	(vi)	 any amendment, alteration or repeal of any provision of the constitutional documents of any of the Group
Companies in a manner that adversely changes or alters the existing voting or other powers, preferences or other special rights, privileges, benefits or restrictions of the Series C Preferred Shares and/or Series C+ Preferred Shares (whether by
merger, consolidation or otherwise); for the avoidance of doubt, issuance of any Equity Securities having rights, preferences or privileges senior to the Series C Preferred Shares and/or Series C+ Preferred Shares for a consideration per share that
is no lower than the subscription price of the Series C Preferred Shares shall not be deemed as the action that adversely changes or alters the existing voting or other powers, preferences or other special rights, privileges, benefits or
restrictions of the Series C Preferred Shares and/or Series C+ Preferred Shares. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 27 

	7.2	 Meetings of the Board.  

Subject to the provisions of the Articles and unless otherwise determined by the vote of a majority of the directors then in office, the Board
shall meet at least quarterly in accordance with an agreed upon schedule. 
  

	7.3	 Successor Indemnification. 

In the event that the Company or any of its successors or assigns (i) consolidates with or merges into any other entity and shall not be
the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers or conveys all or substantially all of its properties and assets to any person or entity, then, and in each such case, to the extent necessary,
proper provision shall be made so that the successors and assigns of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately prior to such transaction, whether in the
Company’s Articles or elsewhere, as the case may be. 
  

	7.4	 Trustee Shareholders. 

The Group Companies, the Founder and the Management Shareholders shall procure that each of the Investors (except for C+ Round Financing
Investors) shall have the right (but not the obligation) if such Investor requires so to designate an individual to hold certain equity interest in the Beijing Subsidiary proportionate to respective equity interests in the Company held by such
Investor respectively. Such Investors shall procure that such individuals (i) enter into the Cooperation Documents and pledge their equity interests in the Beijing Subsidiary along with the Founder and the other shareholders to the WFOE; and
(ii) enter into such necessary documents to adjust their equity ratio in the Beijing Subsidiary accordingly to mirror the shareholding ratio changes in the Company held by such Investor respectively. 

 

	7.5	 Amendment to Cooperation Documents. 

In the event that any provision under the Cooperation Documents is ruled by any relevant Governmental Authority as invalid or unenforceable
under the Laws of the PRC, the Key Holders and the Group Companies shall, subject to the Laws of the PRC, use their best efforts to take, or cause to be taken, such action, to execute and deliver, or cause to be executed and delivered, such
documents and instruments and to do, or cause to be done, all things necessary, proper or advisable to ensure that substantially all of the income generated by the Domestic Companies is consolidated into the WFOE. 

 

	7.6	 Option to Purchase Domestic Companies. 

Subject to PRC laws, so long as each of the Investors still holds any Shares of the Company, each of such Investors shall have the rights (but
not the obligation) to purchase or designate third parties to purchase certain equity interest in the Domestic Companies or any other Group Company proportionate to the equity interest in the Company held by such Investor respectively for nominal
consideration (or for the lowest price that is in compliance with applicable Law), provided that such Investor or its designees agree to enter into the Cooperation Documents. The shareholders of the Domestic Companies or any such other Group Company
shall return any proceeds from such Investor’s exercise of this option to it. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 28 

	7.7	 [Reserved] 

  

	7.8	 Insurance. 

Upon the request from NLVC and/or LYFE and/or Sequoia and/or Evergreen and/or GIC, the Company shall use its reasonable best efforts to obtain
from financially sound and reputable insurers (i) Directors and Officers Liability insurance and (ii) term “key-person” insurance, each in an amount satisfactory to the Board, and will use
reasonable best efforts to cause such insurance policies to be maintained until such time as the Board determines that such insurance should be discontinued. The “key person” policy shall name the Company as loss payee and neither policy
shall be cancelable by the Company without prior approval of the Board including the NLVC Director, LYFE Director, Sequoia Director, GIC Director and Evergreen Director. 

 

	7.9	 Disclosure of Investment Terms. 

The Founder and the Company shall immediately disclose to the Investors any of the agreements, contracts, term sheets, memorandums of
understanding, arrangements, indentures, notes, bonds, loans, instruments, and other legally binding arrangements whether oral or written if the Company or its Shareholders, Directors, employees or Affiliates propose to initiate or take any action
to solicit or support any inquiry, proposal or offer from, furnish any information to or participate in any negotiations or discussions with any third party or enter into any agreement or arrangement regarding any equity or debt, financing, sale,
transfer or otherwise disposal of the Equity Securities of the Company from the date hereof. 
  

	7.10	 Non-Competition with the Group Company. 

Each of the Key Holders hereof undertakes and covenants to each Investor that neither he/she nor any of his/her Affiliates will directly or
indirectly, either by himself/herself or in conjunction with or through any other Person: (i) engage in any business activities in competition with, upstream to or downstream to the business of any Group Company or any Affiliate of the Group
Company, whether such engagement is as a partner, investor (other than as a holder of less than one percent (1%) of the outstanding capital stock of a publicly traded company), consultant, adviser, agent, employee or otherwise, nor to offer
employment to or employ, for himself or on behalf of any then competitor of the Group Company or an Affiliate of the Company; (ii) solicit in any manner any Person who is or has been a customer or client of any Group Company for the purpose of
offering to such Person any goods or services similar to or competing with any of the businesses conducted by any Group Company; (iii) solicit or entice away, or endeavor to solicit or entice away, any employee or officer of any Group Company;
(iv) use any Confidential Information to compete with the Group Company. For the avoidance of doubt, in order to validate and enforce the non-competition obligation of any Key Holder after such Key Holder
is no longer an employee of any Group Companies, the Group Companies shall pay such Key Holder the non-competition compensations if required by the applicable Law. In the event that there is any conflict
between the provisions of any separate agreement executed by any of the relevant Parties with respect to the non-competition obligation of the Key Holders and the provisions of this
Section 7.10, the provisions of this Section 7.10 shall prevail. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 29 

	7.11	 Full Time Commitment.  

 

	 	(a)	 The Founder undertakes and covenants to the Investors that, commencing from the date of this Agreement until
the second anniversary of a Qualified IPO (unless his earlier resignation is approved by the Board, including at least the affirmative votes of the one half (1/2) of the Key Investors’ Directors), he shall commit all of his efforts to
furthering the business of the Group Companies and shall not, without the prior written consent of at least one-half (1/2) of the Key Investors’ Directors, either on his own account or through any of his
Affiliates, or in conjunction with or on behalf of any other Person, (i) possess, directly or indirectly, the power to direct or cause the direction of the management and business operation of any entity other than a Group Company whether
(A) through the ownership of any equity interest in such entity, or (B) by occupying half or more of the board seats of the entity, or (C) by contract or otherwise; or (ii) devote time to carry out or otherwise engage in the
management or the business operation of any entity other than a Group Company. 

  

	 	(b)	 Each Key Holder (other than the Founder) undertakes and covenants to the Investors that, commencing from the
date of this Agreement until the first anniversary of a Qualified IPO (unless his or her earlier resignation is approved by the Board, including at least the affirmative votes of the one half (1/2) of the Key Investors’ Directors), he/she shall
commit all of his/her efforts to furthering the business of the Group Companies and shall not, without the prior written consent of at least one-half (1/2) of the Key Investors’ Directors, either on
his/her own account or through any of his/her Affiliates, or in conjunction with or on behalf of any other Person, (i) possess, directly or indirectly, the power to direct or cause the direction of the management and business operation of any
entity other than a Group Company whether (A) through the ownership of any equity interest in such entity, or (B) by occupying half or more of the board seats of the entity, or (C) by contract or otherwise; or (ii) devote time to
carry out or otherwise engage in the management or the business operation of any entity other than a Group Company. 

  

	 	(c)	 Each Key Holder undertakes and covenants to the Investors that he/she shall comply with the policies,
standards, rules and regulations of the Group Company, and any additions or amendments to such policies, standards, rules or regulations established by the Group Company from time to time. 

 

	 	(d)	 Each Key Holder further agrees that he/she shall, while performing services for the Group Company:
(i) exercise due care as would a good administrator or manager and be faithful and diligent in performing his/her services to the Group Company; (ii) except for the business needs of the Group Company, as expressly authorized by the
Company, not unilaterally act on behalf of or in the name of the Group Company; and (iii) hold in confidence and not disclose to others any information relating to his/her compensation, except for the disclosure to his/her Immediate Family
Members. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 30 

	 	(e)	 Each Key Holder further agrees that, other than is necessary to fulfill his/her responsibilities to any Group
Company, such Key Holder shall not remove or have removed from the Company or an Affiliate of the Company’s premises any notebooks, reports, letters, manuals, listings, data, data bases, drawings, blueprints, notes, sketches, materials,
references, memoranda, documentation, or other materials, directly or indirectly relating to any Confidential Information, including all copies of such material, whether in hard copy, electronic media or in any other form belonging to the Company or
an affiliate of the Company, or their customers, without first obtaining the written consent of the Company or the relevant affiliate of the Company, as the case may be. 

 

	 	(f)	 Without requesting additional compensation from the Company and/or the relevant Affiliate of the Company, each
Key Holder further agrees to sign and execute all documents and other papers and otherwise fully cooperate with the Company and the affiliates of the Company to carry out the intent of Section 7.10 and
Section 7.11. 

  

	 	(g)	 Except as disclosed to the Company and the Founder prior to the Closing, each of the other Key Holders (except
the Founder) shall not, in any manner directly or indirectly, engage in any other business activities, whether such engagement is as a partner, investor, consultant, adviser, agent, employee or otherwise, without the prior written consent of the
Founder, or (i) HAN Yusheng (汉雨生) shall be entitled to purchase any shares purchased and owned by such Key Holder under the Call Option Agreement entered into by HAN Yusheng (汉雨生) and such Key Holder
without payment of any consideration or at nominal consideration, (ii) the Company shall be entitled to redeem all the Preferred Shares held directly or indirectly by such Key Holder at such time at the per share price of Original Preferred
Issue Price and all the other Ordinary Shares, options and equity securities of the Company held directly or indirectly by such Key Holders at such time without payment of any consideration. 

 

	7.12	 [Reserved] 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 31 

	7.13	 Compliance with Anti-corruption Law. 

 

	 	(a)	 Each of the Group Companies covenants that it shall not, and shall not permit any of its Subsidiaries or
Affiliates or any of its or their respective directors, administrators, officers, managers, board of directors (supervisory and management) members, employees, independent contractors, representatives or agents to, promise, authorize or make any
payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any non-U.S. official, in each case, in violation of the Anti-Corruption Laws. The Company
further covenants that it shall, and shall cause each of its Subsidiaries and Affiliates to, cease all of its or their respective activities, as well as remediate any actions taken by the Company, its Subsidiaries or Affiliates, or any of its or
their respective directors, administrators, officers, managers, board of directors (supervisory and management) members, employees, independent contractors, representatives or agents in violation of the Anti-Corruption Laws. The Company further
covenants that it shall, and shall cause each of its Subsidiaries and Affiliates to maintain, immediately upon the execution of this Agreement, books and records that describe in detail and in all material respects the services rendered, payments
made, and costs and expenditures incurred by the Subsidiaries and Affiliates, and to maintain a system of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure that all measures and
transactions go through requisite approval process and have proper authorization and are in compliance with the Anti-Corruption Laws. The use of false documents is prohibited, as is the making of inadequate, ambiguous or deceptive bookkeeping
entries and any other accounting procedure, technique or device that could hide or otherwise disguise the nature of the transaction at issue. The Warrantors shall cause the Company to, maintain a compliance program in terms of anti-corruption
policies, procedures and accounting controls that satisfies the requirements under the Anti-Corruption Laws in all material respect. 

The Group Companies’ use of proceeds will be in compliance with and will not result in the breach of any sanctions administered from time
to time by the Office of Foreign Assets Control of the United States Department of the Treasury (“OFAC”) or the United States Department of State, any regulations or executive orders implementing U.S. economic sanctions Laws, or
other similar sanctions imposed by the United Nations, the European Union under Council Regulation (EC) No. 194/2008, Her Majesty’s Treasury, or any other relevant governmental entity (“Sanctions”). Without limiting the
generality of the foregoing, the Group Companies will not directly or indirectly use, lend, contribute or otherwise make available any proceeds for the purpose of funding or facilitating any activities or business of or with any person towards any
sales or operations in Cuba, Iran, Libya, Syria, the Democratic People’s Republic of Korea, the Crimea Region of Ukraine, or any other country sanctioned by OFAC from time to time, or for the purpose of funding any operations or financing any
investments in, or make any payments to, any Person targeted by or subject to any Sanctions. 
  

	 	(b)	 Each of the Group Companies covenants that it shall, to the extent commercially practicable, use its best
effort to integrate the third party (including, but not limited to, distributors, agents, marketing vendors and business partners) engagement and management into its compliance program, conducting
pre-engagement compliance review, delivering anti-corruption policies and arranging the FCPA and anti-corruption trainings. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 32 

	 	(c)	 Each of the Group Companies covenants that it shall, to the extent commercially practicable, use its best
effort to, and shall cause its Subsidiaries and Affiliates to use its best effort to, conduct, and shall keep the Investors informed for, post-closing review over the Domestic Companies’ existing engagements with the relevant third parties
(including, but not limited to, distributors, agents, marketing vendors and business partners). Each of the Group Companies shall, to the extent commercially practicable, use its best effort to, and shall cause its Subsidiaries and Affiliates to use
its best effort to, conduct, and shall keep the Investors informed for, a review on the list of relevant third parties (including but not limited to, distributors, agents, marketing vendors and business partners) used by the Domestic Companies, the
corresponding services contracts and any documents/financial vouchers that could reflect the nature of the services provided. Each of the Group Companies covenants that it shall, to the extent commercially practicable, use its best effort to, and
will cause its Subsidiaries and Affiliates to use its best effort to take, and shall keep Investors informed for, any potential remediation actions resulted from such third party review. 

 

	 	(d)	 Each of the Group Companies covenants that, to the extent commercially practicable, it shall, and will cause
its Subsidiaries and Affiliates to, hold trainings at regular intervals on FCPA, the applicable Anti-Corruption Laws and the compliance policies, procedures and internal control mechanism adopted by the Group Companies. Each of the Group Companies
covenants that, to the extent commercially practicable, it shall, and will cause its Subsidiaries and Affiliates to, procure the relevant directors, employees, consultants and other representatives of the Group Companies to attend trainings.

  

	 	(e)	 Each of the Group Companies covenants that it shall, and will cause its Subsidiaries and Affiliates to,
immediately report knowledge or suspicion to the Investors, if the Group Companies or any of its Subsidiaries or Affiliates becomes aware, or has reason to suspect, that any person or entity acting on behalf of the Group Companies or its
Subsidiaries/Affiliates has violates materially the Anti-Corruption Laws. 

  

	7.14	 Compliance with Anti-Money Laundering Laws. 

Each of the Group Companies shall, and each Key Holder shall procure that the operations of the Group Companies to, be conducted at all times
in compliance with applicable anti-money laundering statutes of all jurisdictions in all material respect, including, without limitation, all U.S. anti-money laundering laws, the rule and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any governmental or regulatory agency. 
  

	7.15	 Management Incentive.  

 

	 	(a)	 (i) Immediately prior to the closing of a Qualified Financing, or (ii) in the event that the Company has
already completed an initial public offering, immediately after the day when the valuation of the Company is no less than US$2,472,850,866 based on the closing sales prices of Company’s public traded Shares on the relevant stock exchanges,
whichever is earlier, the Company may reserve certain number of additional shares for issuance pursuant to the ESOP (the “New ESOP”) of the Company that accounts for 5% of the share capital of the Company immediately after such
reservation on an as converted and fully diluted basis and the Investors shall vote in favor of the adoption of the New ESOP when any of the abovementioned condition has been satisfied. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 33 

	 	(b)	 The grant of options under the New ESOP shall be approved by the Board (including the approval of at least one
half (1/2) of the Key Investors’ Directors) or approved by a mechanism stipulated by applicable Laws, regulations and rules in the event that the Company has completed an initial public offering. Subject to aforementioned approval requirements,
the Company may grant a certain number of options under the New ESOP to the Founder. 

  

	7.16	 Qualified IPO. 

The Key Holders and the Company undertake to use best efforts to, within three (3) years after the date hereof, consummate a Qualified
IPO. 
  

	7.17	 Term. 

The provisions of this Section 7 (except for 7.11(a), 7.11(b) and 7.15) shall terminate upon the consummation of a
Qualified IPO. 
  

	8.	 MISCELLANEOUS. 

 

	8.1	 Governing Law. 

This Agreement shall be governed by and construed in accordance with the Laws of Hong Kong. 

 

	8.2	 Counterparts. 

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile or other electronic signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 
  

	8.3	 Headings and Subheadings. 

The headings and subheadings used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement. 
  

	8.4	 Notices. 

All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given:
(a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification
of receipt. All communications shall be sent to the respective parties at their address, or to such email address, facsimile number or address as set forth on Schedule II attached hereto or as subsequently modified by written notice
given in accordance with this Section 8.4. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 34 

	8.5	 Costs of Enforcement. 

If any party to this Agreement seeks to enforce its rights under this Agreement by legal proceedings, the
non-prevailing party shall pay all costs and expenses incurred by the prevailing party, including, without limitation, all reasonable legal adviser’s fees. 

 

	8.6	 Amendments and Waivers. 

Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively), only with the written consent of (i) the Company, (ii) the Majority Key Holders, (iii) the Majority Series A Preferred Shares Holders, (iv) the Majority Series A+ Preferred
Shares Holders, (v) the Majority Series B Preferred Shares Holders and (vi) the Majority Series C Preferred Shares Holders. Notwithstanding anything contained herein to the contrary, any waiver or amendment that would have the effect of
altering the rights and obligations of a particular Investor (without taking into account its unique circumstances) in an adverse and different manner than the other Investors shall be effective against such Investor only with its prior written
consent. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities then Outstanding, each future holder of all such Registrable Securities, and the Company. The Company shall
give prompt written notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination or waiver. Any amendment, termination or waiver effected in accordance with this
Section 8.6 shall be binding on all Parties hereto, even if they do not execute such consent. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed
to be, or construed as, a further or continuing waiver of any such term, condition or provision. 
  

	8.7	 Severability. 

The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. 

 

	8.8	 Aggregation of Shares. 

All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the
availability of any rights under this Agreement. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 35 

	8.9	 Entire Agreement. 

This Agreement, the Purchase Agreement, any other Transaction Documents, together with all the schedules and exhibits hereto and thereto, which
are hereby expressly incorporated herein by this reference, constitute the full and entire understanding and agreement among the Parties with regard to the subjects hereof and thereof and supersede all prior agreements and undertakings, both written
and oral, among the Parties with respect to the subject matter hereof and thereof (including without limitations any prior shareholders agreements, any term sheet or letter of intent among any of the Parties with respect to the subject matter of
this Agreement or the other Transaction Documents). 
  

	8.10	 Precedence. 

Upon execution, this Agreement (including the Exhibits hereto, if any) shall replace the Prior Agreement, and supersede any other shareholders
rights agreement pertaining to the Company. Should there be any conflict or discrepancy between the provisions of this Agreement and those of any other shareholders agreements, the provisions of this Agreement shall prevail. 

 

	8.11	 Legend. 

  

	 	(a)	 Each certificate representing Shares of a Key Holder issued by the Company shall be endorsed with the following
legend: 

 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO, AND
IN CERTAIN CASES PROHIBITED BY, THE TERMS AND CONDITIONS OF A CERTAIN SHAREHOLDERS’ AGREEMENT BY AND AMONG THE SHAREHOLDER, THE COMPANY AND CERTAIN OTHER HOLDERS OF SHARES OF THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN
REQUEST TO THE SECRETARY OF THE COMPANY. 
  

	 	(b)	 Each Key Holder agrees that the Company may instruct its transfer agent to impose transfer restrictions on the
shares represented by certificates bearing the legend referred to in Section 8.11(a) above to enforce the provisions of this Agreement, and the Company agrees to promptly do so. The legend shall be removed upon termination
of this Agreement at the request of the Holder. 

  

	8.12	 Dispute Resolution. 

 

	 	(a)	 Any dispute, controversy or claim arising out of or relating to this Agreement, or the interpretation, breach,
termination or validity hereof, shall first be subject to resolution through consultation of the parties to such dispute, controversy or claim. Such consultation shall begin within seven (7) days after one Party hereto has delivered to the
other Parties involved a written request for such consultation. If within thirty (30) days following the commencement of such consultation the dispute cannot be resolved, the dispute shall be submitted to arbitration upon the request of any
Party with notice to the other Parties. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 36 

	 	(b)	 The arbitration shall be conducted in Hong Kong under the auspices of the Hong Kong International Arbitration
Centre (the “HKIAC”). There shall be three arbitrators. The complainant and the respondent to such dispute shall each select one arbitrator within thirty (30) days after giving or receiving the demand for arbitration. Such
arbitrators shall be freely selected, and the Parties shall not be limited in their selection to any prescribed list. The chairman of the HKIAC shall select the third arbitrator, who shall be qualified to practice Law in Hong Kong. If either party
to the arbitration does not appoint an arbitrator who has consented to participate within thirty (30) days after selection of the first arbitrator, the relevant appointment shall be made by the chairman of the HKIAC. 

 

	 	(c)	 The arbitration proceedings shall be conducted in English. The arbitration tribunal shall apply the Arbitration
Rules of the HKIAC in effect at the time of the arbitration. However, if such rules are in conflict with the provisions of this Section 8.12, including the provisions concerning the appointment of arbitrators, the
provisions of this Section 8.12 shall prevail. 

  

	 	(d)	 The arbitrators shall decide any dispute submitted by the parties to the arbitration strictly in accordance
with the substantive Law of Hong Kong and shall not apply any other substantive law. 

  

	 	(e)	 Each Party hereto shall cooperate with any party to the dispute in making full disclosure of and providing
complete access to all information and documents requested by such party in connection with such arbitration proceedings, subject only to any confidentiality obligations binding on the Party receiving the request. 

 

	 	(f)	 The award of the arbitration tribunal shall be final and binding upon the disputing parties, and any party to
the dispute may apply to a court of competent jurisdiction for enforcement of such award. 

  

	 	(g)	 Any party to the dispute shall be entitled to seek preliminary injunctive relief, if possible, from any court
of competent jurisdiction pending the constitution of the arbitral tribunal. 

  

	8.13	 Delays or Omissions. 

No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other
party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any
such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in
writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 37 

	8.14	 Conflict with Articles. 

In the event of any conflict or inconsistency between the provisions of this Agreement and the provisions of the Company’s Articles or
other constitutional documents, the terms of this Agreement shall prevail as between the shareholders of the Company only. The Investors and the Key Holders shall, notwithstanding the conflict or inconsistency, act so as to effect the intent of this
Agreement to the greatest extent possible under the circumstances and shall promptly amend the conflicting constitutional documents to conform to this Agreement to the greatest extent possible. 

 

	8.15	 Holding Companies. 

Each of the Key Holders who are natural persons shall procure the corporate Key Holder controlled by him to fully comply with and perform all
of the obligations, covenants, undertakings and commitments of such corporate Key Holder under this Agreement. 
  

	8.16	 Independent Nature of Investors’ Obligations and Rights. 

The obligations of each Investor under this Agreement and the other Transaction Documents are several and not joint, and except for the
Affiliate of such Investor, no Investor is responsible in any way for the performance or conduct of any other Investor in connection with the transactions contemplated hereby. Nothing contained herein or in any other Transaction Document, and no
action taken by any Investor pursuant hereto or thereto, shall be or shall be deemed to constitute a partnership, association, joint venture, or joint group with respect to the Investors. Each Investor agrees that no other Investor has acted as an
agent for such Investor in connection with the transactions contemplated hereby. 
  

	8.17	 Restriction on the Use of “Sequoia” and Confidentiality. 

Without the written consent of Sequoia, the Group Companies, their shareholders (excluding Sequoia), and the Founder, shall not use the name or
brand of Sequoia or its Affiliate, claim itself as a partner of Sequoia or its Affiliate, make any similar representations. Without the written approval of Sequoia, the Group Companies, their shareholders (excluding Sequoia), and the Founder, shall
not make or cause to be made, any press release, public announcement or other disclosure to any third party in respect of this Agreement or Sequoia’s subscription of share interest of the Company. 

 

	8.18	 Restriction on the Use of “GIC” and Confidentiality. 

Without the written consent of GIC, each Party shall not use the name or brand of GIC or its Affiliate, claim itself as a partner of GIC or its
Affiliate, make any similar representations. Without the written approval of GIC, each Party shall not make or cause to be made, any press release, public announcement or other disclosure to any third party in respect of this Agreement or GIC’s
subscription of share interest of the Company. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 38 

	8.19	 Restriction on the Use of “LAV” and Confidentiality. 

Without the written consent of LAV, each Party shall not use the name or brand of LAV or its Affiliate, claim itself as a partner of LAV or its
Affiliate, make any similar representations. Without the written approval of LAV, each Party shall not make or cause to be made, any press release, public announcement or other disclosure to any third party in respect of this Agreement or LAV’s
subscription of share interest of the Company. 
  

	8.20	 Restriction on the Use of “OrbiMed” and Confidentiality. 

Without the written consent of OrbiMed, each Party shall not use the name or brand of OrbiMed or its Affiliate, claim itself as a partner of
OrbiMed or its Affiliate, make any similar representations. Without the written approval of OrbiMed, each Party shall not make or cause to be made, any press release, public announcement or other disclosure to any third party in respect of this
Agreement or OrbiMed’s subscription of share interest of the Company. 
  

	8.21	 SAFE Registration. 

With respect to any holder or beneficial owner of any equity security of the Company (other than any direct or indirect holder or beneficial
owner of the Investors) (each, a “Security Holder”) who is a “Domestic Resident” as defined in Circular 37 and is subject to the SAFE registration or reporting requirements under Circular 37, such Security Holder shall,
and the Key Holders and the Group Companies shall cause such Security Holder to comply with the applicable SAFE registration or reporting requirements under SAFE Rules and Regulations. 

 

	8.22	 IPO Participation Right. 

Notwithstanding and without prejudice to Section 4 above but subject to applicable laws and regulations, GIC shall
have the right to purchase by itself or its Affiliates, at its option, at the final price per share set forth in the Company’s final prospectus with respect to an IPO, up to the number of the Ordinary Shares of the Company offered in the IPO
that enable GIC and/or Affiliates to maintain, in the aggregate, its ownership interest percentage in the Company immediately prior to the consummation of the IPO. This provision shall terminate immediately after the consummation of a Qualified IPO.

  

	8.23	 Preferred Shares held by Ordinary Shareholders and their Affiliates.  

For the avoidance of doubt, and notwithstanding anything to the contrary hereunder, any rights enjoyed by Key Holders and any other Ordinary
Shareholders as an “Investor”, “Holder”, “Eligible Holder” or a holder of Preferred Shares under this Agreement, shall be in respect of, and limited to, the extent of such number of Preferred Shares from time to
time held by it and the exercise of such rights shall in no event affect and contradict the obligations and restrictions otherwise placed on it and its Affiliates (including such capacities as “Key Holder”, “Founder”
“Holding Entity” or “Management Shareholder”, as appropriate) pursuant to the terms of this Agreement. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 39 

 [Remainder of Page Intentionally Left Blank] 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
  
 40 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first above written. 
  

							
	COMPANY:	 		 	BURNING ROCK BIOTECH LIMITED
				
		 		 	By:	 	 /s/ HAN Yusheng

		 		 	 Name: HAN Yusheng (汉雨生)

Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first above written. 
  

							
	HK COMPANY:	 		 	BR Hong Kong Limited
				
		 		 	By:	 	 /s/ HAN Yusheng

		 		 	 Name: HAN Yusheng
 Title:
Director

			
	WFOE:	 		 	 BEIJING BURNING ROCK BIOTECH LIMITED

(北京博宁洛克生物科技有限公司) (Seal)

				
		 		 	By:	 	 /s/ HAN Yusheng

		 		 	 Name: HAN Yusheng
 Title: Legal
Representative

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first above written. 
  

							
	DOMESTIC COMPANIES:	 		 	Burning Rock (Beijing) Biotechnology Co., Ltd. (燃石(北京)生物科技有限公司) (Seal)
				
		 		 	By:	 	 /s/ HAN Yusheng

		 		 	 Name: HAN Yusheng (汉雨生)

Title: Legal Representative

			
		 		 	Guangzhou Burning Rock Dx Co., Ltd. (广州燃石医学检验所有限公司) (Seal)
				
		 		 	By:	 	 /s/ HAN Yusheng

		 		 	 Name: HAN Yusheng (汉雨生)

Title: Legal Representative

			
		 		 	Guangzhou Burning Rock Biotechnology Co., Ltd. (广州燃石生物科技有限公司) (Seal)
				
		 		 	By:	 	 /s/ HAN Yusheng

		 		 	 Name: HAN Yusheng (汉雨生)

Title: Legal Representative

			
		 		 	Guangzhou Burning Rock Medical Equipment Co., Ltd. (广州燃石医疗器械有限公司) (Seal)
				
		 		 	By:	 	 /s/ HAN Yusheng

		 		 	 Name: HAN Yusheng (汉雨生)

Title: Legal Representative

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	DOMESTIC COMPANIES:	  		 	Burning Rock Biotechnology (Shanghai) Co., Ltd. (燃石生物科技(上海)有限公司) (Seal)
				
		  		 	By:	 	 /s/ HAN Yusheng

		  		 	 Name: HAN Yusheng (汉雨生)

Title: Legal Representative

			
	FOUNDER:	  		 	
				
		  		 	By:	 	 /s/ HAN Yusheng    

		  		 	Name: HAN Yusheng (汉雨生)

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	HOLDING ENTITIES:	 		 	Quantum Boundary Holdings Limited
				
		 		 	By:	 	 /s/ HAN Yusheng

		 		 	Name: HAN Yusheng (汉雨生)
		 		 	Title: Director
			
		 		 	Golden Dusk International Limited
				
		 		 	By:	 	 /s/ ZHOU Nannan

		 		 	Name: ZHOU Nannan (周楠楠)
		 		 	Title: Director
			
		 		 	Miraculous Dream International Limited
				
		 		 	By:	 	 /s/ WU Zhigang

		 		 	Name: WU Zhigang (吴志刚)
		 		 	Title: Director
			
		 		 	Zephyr Guardian International Limited
				
		 		 	By:	 	 /s/ SHAO Liang

		 		 	Name: SHAO Liang (邵量)
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	HOLDING ENTITIES:	 		 	Silver Cygnus Holdings Limited
				
		 		 	By:	 	 /s/ ZHOU Dan

		 		 	Name: ZHOU Dan (周丹)
		 		 	Title: Director
			
		 		 	Quantum Intelligence Holding Limited
				
		 		 	By:	 	 /s/ SI Peijing

		 		 	Name: SI Peijing (斯佩静)
		 		 	Title: Director
			
		 		 	Loving Marvin Holdings Limited
				
		 		 	By:	 	 /s/ CHUAI Shaokun

		 		 	Name: CHUAI Shaokun (揣少坤)
		 		 	Title: Director
			
		 		 	Quantum Intelligence Group Limited
				
		 		 	By:	 	 /s/ LIU Hao

		 		 	Name: LIU Hao (刘颢)
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	HOLDING ENTITIES:	 		 	Winter Elves International Limited
				
		 		 	By:	 	 /s/ ZHOU Nannan

		 		 	Name: ZHOU Nannan (周楠楠)
		 		 	Title: Director
			
		 		 	Winter Elves Holdings Limited
				
		 		 	By:	 	 /s/ WU Zhigang

		 		 	Name: WU Zhigang (吴志刚)
		 		 	Title: Director
			
		 		 	Quantum Intelligence Developments Limited
				
		 		 	By:	 	 /s/ TAN Zhaolei

		 		 	Name: TAN Zhaolei (谈兆蕾)
		 		 	Title: Director
			
		 		 	Interstellar Gate Holdings Limited
				
		 		 	By:	 	 /s/ Leo Li

		 		 	Name: Leo Li (李晋翔)
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	HOLDING ENTITIES:	 		 	Gentle Drizzle Group Limited
				
		 		 	By:	 	 /s/ ZHOU Dan

		 		 	Name: ZHOU Dan (周丹)
		 		 	Title: Director
			
		 		 	Gentle Drizzle International Limited
				
		 		 	By:	 	 /s/ ZHOU Nannan

		 		 	Name: ZHOU Nannan (周楠楠)
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	MANAGEMENT SHAREHOLDERS:	 		 	
				
		 		 	By:	 	 /s/ SHAO Liang

		 		 	Name: SHAO Liang (邵量)
				
		 		 	By:	 	 /s/ ZHOU Dan

		 		 	Name: ZHOU Dan (周丹)
				
		 		 	By:	 	 /s/ CHUAI Shaokun

		 		 	Name: CHUAI Shaokun (揣少坤)
				
		 		 	By:	 	 /s/ WU Zhigang

		 		 	Name: WU Zhigang (吴志刚)

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	By:	 	 /s/ YIN Dong

	Name: YIN Dong (尹东)
		
	By:	 	 /s/ SI Peijing

	Name: SI Peijing (斯佩静)

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	A ROUND FINANCING INVESTORS:	 		 	Northern Light Venture Capital III, Ltd.
				
		 		 	By:	 	 /s/ Jeffrey D. Lee

		 		 	Name: Jeffrey D. Lee
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	A ROUND FINANCING INVESTORS:	 		 	Crest Top Developments Limited
	A+ ROUND FINANCING INVESTORS:	 		 		 	
	B ROUND FINANCING INVESTORS:	 		 		 	
		 		 	By:	 	 /s/ WANG Mingyao

		 		 	Name: WANG Mingyao (王明耀)
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	A+ ROUND FINANCING INVESTORS:	 		 	LYFE Capital Stone (Hong Kong) Limited
	B ROUND FINANCING INVESTORS:	 		 		 	
	C ROUND FINANCING INVESTORS:	 		 		 	
				
		 		 	By:	 	 /s/ ZHAO Jin

		 		 	Name: ZHAO Jin
		 		 	Title: Founding Partner

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	A+ ROUND FINANCING INVESTORS:	 		 	SCC Venture V Holdco I, Ltd.
	B ROUND FINANCING INVESTORS:	 		 		 	
				
		 		 	By:	 	 /s/ Ip Siu Wai Eva

		 		 	Name: Ip Siu Wai Eva
		 		 	Title: Authorized Signatory

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	A+ ROUND FINANCING INVESTORS:	 		 	Anssence Investments Limited
	B ROUND FINANCING INVESTORS:	 		 		 	
				
		 		 	By:	 	 /s/ LIU Lin

		 		 	Name: LIU Lin
		 		 	Title: Authorized Signatory

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	B ROUND FINANCING INVESTORS:	 		 	SCC Venture VI Holdco, Ltd.
	C ROUND FINANCING INVESTORS:	 		 		 	
				
		 		 	By:	 	 /s/ Ip Siu Wai Eva

		 		 	Name: Ip Siu Wai Eva
		 		 	Title: Authorized Signatory

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	B ROUND FINANCING INVESTORS:	 		 	EverGreen SeriesC Limited Partnership
	C ROUND FINANCING INVESTORS:	 		 	acting through CMB International Asset
		 		 	Management Limited as its general partner
			
		 		 	 /s/ JIANG RONG FENG

		 		 	Name: JIANG RONG FENG
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	C ROUND FINANCING INVESTORS:	 		  	Owap Investment Pte Ltd
			
		 		  	 /s/ Lau Eng Boon

		 		  	Name: Lau Eng Boon
		 		  	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	C ROUND FINANCING INVESTORS:	 		 	CMBI Private Equity Series SPC on
		 		 	behalf of and for the account of
		 		 	Biotechnology Fund IV SP
			
		 		 	 /s/ JIANG RONG FENG

		 		 	Name: JIANG RONG FENG
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	C ROUND FINANCING INVESTORS:	 		 	LAV Biosciences Fund V, L.P.
	C+ ROUND FINANCING INVESTORS:	 		 	
			
		 		 	By: LAV GP V, L.P.
		 		 	Its General Partner
		 		 	By: LAV Corporate V GP, Ltd.
		 		 	Its: General Partner
			
		 		 	 /s/ Yu Luo

		 		 	Name: Yu Luo
		 		 	Title: Authorized Signatory

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	C ROUND FINANCING INVESTORS:	 		 	LYFE Mount Whitney Limited
			
		 		 	 /s/ ZHAO Jin

		 		 	Name: ZHAO Jin
		 		 	Title: Authorized Signatory

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	C ROUND FINANCING INVESTORS:	 		 	A5J Ltd
			
		 		 	 /s/ Edmond Ng

		 		 	Name: Edmond Ng
		 		 	Title: Managing Partner

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	C ROUND FINANCING INVESTORS:	 		 	Unique Invest Co., Ltd
			
		 		 	 /s/ SHU Weiping

		 		 	Name: SHU Weiping
		 		 	Title: Authorized Signatory

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	C ROUND FINANCING INVESTORS:	 		 	Ampere Partners Holdings Limited
			
		 		 	 /s/ Thomas Crawford Jamieson

		 		 	Name: Thomas Crawford Jamieson
		 		 	Title: Director

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	C+ ROUND FINANCING INVESTORS:	 		 	ORBIMED PARTNERS MASTER FUND LIMITED
				
		 		 	        By:	 	OrbiMed Capital LLC, solely in its
		 		 		 	capacity as Investment Advisor 
			
		 		 	 /s/ Geoffrey Hsu

		 		 	Name: Geoffrey Hsu
		 		 	 Title: Member

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	C+ ROUND FINANCING INVESTORS:	 		 	THE BIOTECH GROWTH TRUST PLC
				
		 		 	By:	 	 OrbiMed Capital LLC, solely in its
 capacity as
Portfolio Manager 

			
		 		 	 /s/ Geoffrey Hsu

		 		 	Name: Geoffrey Hsu
		 		 	Title: Member

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	C+ ROUND FINANCING INVESTORS:	 		 	WORLDWIDE HEALTHCARE TRUST PLC
				
		 		 		 	 By: OrbiMed Capital LLC, solely in its
 capacity
as Portfolio Manager 

			
		 		 	 /s/ Geoffrey Hsu

		 		 	Name: Geoffrey Hsu
		 		 	Title: Member

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

							
	C+ ROUND FINANCING INVESTORS:	 	ORBIMED GENESIS MASTER FUND, L.P.
			
		 		 	 By: OrbiMed Genesis GP, LLC, its

General Partner

				
		 		 		 	 By: OrbiMed Advisors LLC, its
 Managing Member

		
		 	 /s/ Geoffrey Hsu

		 	Name: Geoffrey Hsu
		 	Title: Member

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the Parties have executed this Shareholders’ Agreement as of the
date first written above. 
  

					
	C+ ROUND FINANCING INVESTORS:	 		 	CASDIN PARTNERS MASTER FUND, L.P.
			
		 		 	By: Casdin Partners GP, LLC, its General Partner
			
		 		 	 /s/ Kevin O’Brien

		 		 	Name: Kevin O’Brien
		 		 	Title: Authorized Signatory

  
 BURNING ROCK BIOTECH
LIMITED 
 SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

 APPENDIX A 

DEFINITIONS 
 For purposes of this
Agreement, capitalized terms shall have the meanings set forth in this Appendix A. 
  

	1.	 The term “10% U.S. Investor” has the meaning ascribed to such term in
Section 3.3(b). 

  

	2.	 The term “A Round Financing Investors”, “A+ Round Financing Investors”, or
“B Round Financing Investors”, “C Round Financing Investors” or “C+ Round Financing Investors” has the meaning ascribed to such term in the Preamble to this Agreement. 

 

	3.	 The term “Additional Equity Securities” has the meaning set forth in the Articles.

  

	4.	 The term “Additional Proposed Transfer Notice” has the meaning ascribed to such term in
Section 6.2(c)(iv). 

  

	5.	 The term “Additional Transfer Share” has the meaning ascribed to such term in
Section 6.2(b)(iv). 

  

	6.	 The term “Adherence Agreement” has the meaning ascribed to such term in
Section 6.6(a). 

  

	7.	 The term “Affiliate” means, with respect to any individual, corporation, partnership,
association, trust, or any other entity (in each case, a “Person”), any Person which, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation any general partner,
officer or director of such Person and any venture capital fund now or hereafter existing which is controlled by or under common control with one or more general partners or shares the same management company with such Person. Notwithstanding the
foregoing, the parties acknowledge and agree that (a) the name “Sequoia Capital” is commonly used to describe a variety of entities (collectively, the “Sequoia Entities”) that are affiliated by ownership or
operational relationship and engaged in a broad range of activities related to investing and securities trading and (b) notwithstanding any other provision of this Agreement to the contrary, this Agreement shall not be binding on, or restrict
the activities of, any (i) Sequoia Entity outside of the Sequoia China Sector Group or (ii) entity primarily engaged in investment and trading in the secondary securities market. For purposes of the foregoing, the “Sequoia China
Sector Group” means all Sequoia Entities (whether currently existing or formed in the future) that are principally focused on companies located in, or with connections to, the People’s Republic of China. 

 

	8.	 The term “Affiliated Fund” shall mean an affiliated fund or entity of any Investor, which
means with respect to a limited liability company or a limited liability partnership, a fund or entity managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under
common control with such manager or managing member or general partner or management company. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-1 

	9.	 The term “Agreement” has the meaning ascribed to such term in the Preamble to this Agreement.

  

	10.	 The term “Ampere Partners” means Ampere Partners Holding Limited. 

 

	11.	 The term “Anti-Corruption Laws” shall mean the United States Foreign Corrupt Practices Act of
1977, as amended, the United Kingdom Bribery Act 2010, as amended, the Criminal Law of the People’s Republic of China, as amended, the Anti-Unfair Competition Law of the People’s Republic of China, as amended, the Hong Kong Prevention of
Bribery Ordinance (as amended), and any other applicable anti-corruption or anti-bribery laws or regulations. 

  

	12.	 The term “Articles” means the Company’s Eighth Amended and Restated Memorandum and
Articles of Association adopted on January 10, 2020, as amended from time to time. 

  

	13.	 The term “as-exercised” or any variation thereof with
respect to the GIC Warrant means that, prior to the expiration of the Exercise Period of such GIC Warrant, the calculation should be made assuming the full exercise of the purchase right in relation to the Shares pursuant to the GIC Warrant
(“Deemed Exercise”). For the avoidance of doubt, if GIC has not exercised the GIC Warrant upon the expiration of the Exercise Period, the Deemed Exercise shall elapse. 

 

	14.	 The term “Auditor” means the Person for the time being performing the duties of auditors of
the Company. 

  

	15.	 The term “Axiom” means A5J Ltd. 

 

	16.	 The term “Beijing Subsidiary” has the meaning ascribed to such term in the Preamble to this
Agreement. 

  

	17.	 The term “Board” or “Board of Directors” means the Company’s board of
directors. 

  

	18.	 The term “Budget” has the meaning ascribed to such term in
Section 3.1(d). 

  

	19.	 The term “Business Day” means any day, other than a Saturday, Sunday or other day on which the
commercial banks in Beijing, Cayman Islands, Singapore and Hong Kong are authorized or required to be closed for the conduct of regular banking business. 

  

	20.	 The term “Captive Structure” has the meaning ascribed to such term in the Purchase Agreement.

  

	21.	 The term “Casdin” means Casdin Partners Master Fund, L.P. 

 

	22.	 The term “CFC” has the meaning ascribed to such term in
Section 3.3(b). 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-2 

	23.	 The term “Circular 37” means the Circular on the Management of Offshore Investment and
Financing and Round-Trip Investment by Domestic Residents through Special Purpose Vehicles issued by the State Administration of Foreign Exchange issued by SAFE on July 4, 2014, including any of its applicable implementing rules or
regulations. 

  

	24.	 The term “Closing” has the meaning ascribed to it in Section 1.3(a)
of the Purchase Agreement. 

  

	25.	 The term “CMBI” means Evergreen and CMBI Private Equity Series SPC on behalf of and for the
account of Biotechnology Fund IV SP. 

  

	26.	 The term “Code” has the meaning ascribed to such term in
Section 3.3(b). 

  

	27.	 The term “Company” has the meaning ascribed to such term in the Preamble to this Agreement.

  

	28.	 The term “Company’s ROFR Exercise Period” has the meaning ascribed to such term in
Section 6.2(c)(i). 

  

	29.	 The term “Confidential Information” means (i) all trade secrets, proprietary information,
business plans and arrangements, customer lists, marketing materials, financial information, personnel information, survey, statistics, forecast and projections, and any other information of confidentiality nature belonging to the Group Companies
and (iii) any information furnished by an Investor, including but not limited to any Investor’s names, trademarks, and logo. 

  

	30.	 The term “Control” means, with respect to any third party, shall have the meaning ascribed to
it in Rule 405 under the Securities Act, and shall be deemed to exist for any Person (a) when such Person holds at least fifty percent (50%) of the outstanding voting securities of such third party and no other party owns a greater number of
outstanding voting securities of such third party, (b) when such party has the power to control the composition of a majority of the board of directors of such third party, (c) when such party otherwise has the power and authority to
direct the business, management and policies of such third party, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise, or (d) over other members of such party’s Immediate Family Members.

  

	31.	 The term “Cooperation Documents” has the meaning ascribed to such term in the Purchase
Agreement. 

  

	32.	 The term “Co-Sale Eligible Holder” has the meaning
ascribed to such term in Section 6.3(a). 

  

	33.	 The term “Co-Sale Eligible Shares” has the meaning
ascribed to such term in Section 6.3(a). 

  

	34.	 The term “Co-Sale Closing” has the meaning ascribed to
such term in Section 6.3(c). 

  

	35.	 The term “Co-Sale Period” has the meaning ascribed to
such term in Section 6.3(a). 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-3 

	36.	 The term “Co-Sale Pro Rata Portion” has the meaning
ascribed to such term in Section 6.3(b). 

  

	37.	 The term “CTD” shall mean Crest Top Developments Limited. 

 

	38.	 The term “Deemed Liquidation Event” has the meaning ascribed to it in the Articles.

  

	39.	 The term “Direct Competitor of the Company” has the meaning ascribed to such term in
Section 6.1(c) (iii). 

  

	40.	 The term “Director” means a member of the Board. 

 

	41.	 The term “Disclosing Party” has the meaning ascribed to such term in
Section 3.6(d). 

  

	42.	 The term “Domestic Company” or “Domestic Companies” has the meaning ascribed
to such term in the Preamble to this Agreement. 

  

	43.	 The term “Eligible Holder” means any holder of no less than 400,000 Registrable Securities (as
adjusted for any share splits, share dividends, recapitalizations or the like). 

  

	44.	 The term “Eligible Holders’ ROFR Exercise Period” has the meaning ascribed to such term
in Section 6.2(b)(i). 

  

	45.	 The term “Equity Securities” means, with respect to a given Person, any share, share capital,
registered capital, ownership interest, partnership interest, equity interest, joint venture or other ownership interest of such Person, or any option, warrant, or right to subscribe for, acquire or purchase any of the foregoing, or any other
security or instrument convertible into or exercisable or exchangeable for any of the foregoing, or any equity appreciation, phantom equity, equity plan or similar right with respect to such Person, or any contract of any kind for the purchase or
acquisition from such person of any of the foregoing, either directly or indirectly. 

  

	46.	 The term “Evergreen” shall mean EverGreen SeriesC Limited Partnership. 

 

	47.	 The term “Evergreen Director” has the meaning ascribed to such term in
Section 5.1(b). 

  

	48.	 The term “Exchange Act” means the United States Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder, or any comparable law of any other jurisdiction in which the Company’s Shares are subject to regulation. 

 

	49.	 The term “Exercise Period” has the meaning ascribed to such term in the GIC Warrant.

  

	50.	 The term “FCPA” means Foreign Corrupt Practices Act of the United States of America, as
amended from time to time. 

  

	51.	 The term “Financial Controller” means any person jointly appointed by the Board who shall have
completed authority over all financial activities and compliance to the financial plan approved by the Board and who should provide report of significant financial transactions at the request of Investors or both of the Key Investors’
Directors. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-4 

	52.	 The term “First Refusal Expiration Notice” has the meaning ascribed to such term in
Section 6.2(f). 

  

	53.	 The term “Form F-3” means such form under the
Securities Act as in effect on the date hereof (including Form S-3 or Form F-3, as appropriate) or any registration form under the Securities Act subsequently adopted by
the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

  

	54.	 The term “Founder” means HAN Yusheng (汉雨生). 

 

	55.	 The term “Fully Exercising Holder” has the meaning ascribed to such term in
Section 4.1(c). 

  

	56.	 The term “GIC” means Owap Investment Pte Ltd, together with its successors, transferees and
permitted assigns. 

  

	57.	 The term “GIC Director” has the meaning ascribed to such term in
Section 5.1(b). 

  

	58.	 The term “GIC Warrant” means has the meaning ascribed to such term in the Purchase Agreement.

  

	59.	 The term “Group Companies” has the meaning ascribed to such term in the Preamble to this
Agreement. 

  

	60.	 The term “Guangzhou Laboratories Subsidiary”, “Guangzhou Biotechnology
Subsidiary” and “Guangzhou Equipment Subsidiary” have the meaning ascribed to such terms in the Preamble to this Agreement. 

  

	61.	 The term “HK Company” has the meaning ascribed to such term in the Preamble to this Agreement.

  

	62.	 The term “HKIAC” has the meaning ascribed to such term in
Section 8.12(b). 

  

	63.	 The term “Holder” means, for purposes of Appendix B, any person owning or having the
rights to acquire Registrable Securities or any permitted assignee of record of such Registrable Securities to whom rights under Appendix B have been duly assigned in accordance with this Agreement. 

 

	64.	 The term “Holding Entity” has the meaning ascribed to such term in the Preamble to this
Agreement. 

  

	65.	 The term “Hong Kong” means the Hong Kong Special Administrative Region of the PRC.

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-5 

	66.	 The term “Immediate Family Member” means a child, stepchild, grandchild, parent,
step-parent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including adoptive relationships, of a
person referred to herein. 

  

	67.	 The term “Initiating Holders” has the meaning ascribed to such term in
Section 2.2(a) of Appendix B. 

  

	68.	 The term “Investor” or “Investors” has the meaning ascribed to such term in
the Preamble to this Agreement. 

  

	69.	 The term “Investor’s Designated Party” has the meaning ascribed to it in
Section 6.6(b). 

  

	70.	 The term “Investors’ Directors” has the meaning ascribed to it in
Section 5.1(b). 

  

	71.	 The term “IPO” means the Company’s first underwritten public offering of its Ordinary
Shares and listing on an internationally-recognized securities exchange. 

  

	72.	 The term “Key Holder” or “Key Holders” has the meaning ascribed to such term
in the Preamble to this Agreement. 

  

	73.	 The term “Key Investors’ Directors” means any Director appointed by an Investor holding
no less than five percent (5%) of the total issued and outstanding Shares on an as converted and as-exercised basis. 

  

	74.	 The term “LAV” means LAV Biosciences Fund V, L.P., together with its successors, transferees
and permitted assignees. 

  

	75.	 The term “Law” means any constitutional provision, statute or other law, rule, regulation,
official policy or interpretation of any Governmental Authority and any injunction, judgment, order, ruling, assessment or writ issued by any Governmental Authority. 

 

	76.	 The term “List of Transferees” has the meaning ascribed to it in
Section 6.1(d)(i). 

  

	77.	 The term “Loss of Control” shall mean any termination of, unapproved amendment to or material
breach of any contracts (including but not limited to the Cooperation Documents) among the Group Companies designed to provide the Company with control over, and the ability to consolidate the financial statements of, direct or indirect subsidiaries
and/or controlled entities. 

  

	78.	 The term “LYFE” shall mean LYFE Capital Stone (Hong Kong) Limited. 

 

	79.	 The term “LYFE Director” has the meaning ascribed to such term in
Section 5.1(b). 

  

	80.	 The term “LYFE II” shall mean LYFE Mount Whitney Limited. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-6 

	81.	 The term “Majority Key Holders” shall mean the Key Holders that hold at least fifty percent
(50%) of the issued and outstanding Ordinary Shares then held by all of the Key Holders. 

  

	82.	 The term “Majority Preferred Shares Holders” shall mean the holders of at least fifty percent
(50%) of the then issued and outstanding Preferred Shares, voting together as a single class on an as-if-converted and
as-exercised basis. 

  

	83.	 The term “Majority Series A Preferred Shares Holders” shall mean the holders of at least fifty
percent (50%) of the then issued and outstanding Series A Preferred Shares, voting together as a single class on an as converted basis. 

  

	84.	 The term “Majority Series A+ Preferred Shares Holders” shall mean the holders of at least
fifty percent (50%) of the then issued and outstanding Series A+ Preferred Shares, voting together as a single class on an as converted basis. 

  

	85.	 The term “Majority Series B Preferred Shares Holders” shall mean the holders of at least sixty-two percent (62%) of the then issued and outstanding Series B Preferred Shares, voting together as a single class on an as converted basis. 

 

	86.	 The term “Majority Series C Preferred Shares Holders” shall mean the holders of at least
fifty-five percent (55%) of the then issued and outstanding Series C Preferred Shares and Series C+ Preferred Shares, voting together as a single class on an as converted and as-exercised basis.

  

	87.	 The term “New ESOP” has the meaning ascribed to such term in
Section 7.15(a). 

  

	88.	 The term “NGS” has the meaning ascribed to such term in
Section 6.1(c)(iii). 

  

	89.	 The term “NLVC” means Northern Light Venture Capital III, Ltd. 

 

	90.	 The term “NLVC Director” has the meaning ascribed to such term in
Section 5.1(b). 

  

	91.	 The term “OrbiMed” means OrbiMed Partners Master Fund Limited, Worldwide Healthcare Trust PLC,
The Biotech Growth Trust PLC and OrbiMed Genesis Master Fund, L.P. 

  

	92.	 The term “OFAC” has the meaning ascribed to such term in
Section 7.13(a). 

  

	93.	 The term “Offer Notice” has the meaning ascribed to such term in
Section 4.1(a). 

  

	94.	 The term “Observer” has the meaning ascribed to such term in
Section 3.4(a). 

  

	95.	 The term “Offerees” has the meaning ascribed to such term in
Section 4.1. 

  

	96.	 The term “on an as converted basis” shall mean assuming the conversion, exercise and exchange
of all securities, directly or indirectly, convertible, exercisable or exchangeable into or for Ordinary Shares, including without limitation the Preferred Shares. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-7 

	97.	 The term “Ordinary Directors” has the meaning ascribed to such term in
Section 5.1(a). 

  

	98.	 The term “Ordinary Shares” means ordinary shares of the Company, par value US$0.0001 per
share. 

  

	99.	 The term “Ordinary Shareholder” means the direct and/or indirect holder of any Ordinary Shares
(other than Ordinary Shares converted from Preferred Shares), which for the avoidance of doubt include but not limited to the Key Holders, YIN Dong (尹东) and SI Peijing (斯佩静). 

 

	100.	 The term “Original Preferred Issue Price” has the meaning set forth in the Articles.

  

	101.	 The term “Over-Purchasing Holder” as the meaning ascribed to such term in
Section 6.2(b)(iv). 

  

	102.	 The term “Party” or “Parties” shall mean the parties to this Agreement, as
set forth in the Preamble. 

  

	103.	 The term “Person” means any natural person, firm, partnership, association, corporation,
company, trust, public body or government. 

  

	104.	 The term “PFIC” has the meaning ascribed to such term in
Section 3.3(b). 

  

	105.	 The term “Pipelines” has the meaning ascribed to such term in
Section 6.1(c)(iii). 

  

	106.	 The term “PRC” means the People’s Republic of China, which for purposes of this Agreement
excludes Hong Kong, the Macau Special Administrative Region and Taiwan. 

  

	107.	 The term “PRC GAAP” means generally accepted accounting principles in effect in the
People’s Republic of China from time to time 

  

	108.	 The term “Preferred Shares” means any and all preferred shares outstanding and to be issued by
the Company, including but not limited to Series A Preferred Shares, Series A+ Preferred Shares, Series B Preferred Shares, Series C Preferred Shares and Series C+ Preferred Shares. 

 

	109.	 The term “Preferred Shares Transferee” has the meaning ascribed to such term in
Section 6.1(c)(i). 

  

	110.	 The term “Preferred Shares Transferor” has the meaning ascribed to such term in
Section 6.1(c)(i). 

  

	111.	 The term “Prior Agreement” has the meaning ascribed to such term in Recitals. 

  

	112.	 The term “Pro Rata Share” has the meaning ascribed to such term in
Section 4.1(b). 

  

	113.	 The term “Prohibited Transfer” has the meaning ascribed to such term in
Section 6.5(c). 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-8 

	114.	 The term “Proposed Sale” has the meaning ascribed to such term in
Section 6.1(c)(i). 

  

	115.	 The term “Proposed Transfer” has the meaning ascribed to such term in
Section 6.2(a). 

  

	116.	 The term “Proposed Transfer Notice” has the meaning ascribed to such term in
Section 6.2(a). 

  

	117.	 The term “Prospective Transferee” means any person to whom a Key Holder proposes to make a
Proposed Transfer. 

  

	118.	 The term “Purchase Agreement” has the meaning ascribed to such term in Recitals.

  

	119.	 The term “Purchasing Holders” as the meaning ascribed to such term in
Section 6.2(b)(iv). 

  

	120.	 The term “Purchase Right” has the meaning ascribed to such term in
Section 6.1(c)(ii). 

  

	121.	 The term “Purchase Right Exercise Period” has the meaning ascribed to such term in
Section 6.1(c)(ii). 

  

	122.	 The term “Qualified Financing” shall mean equity financing of the Company occurring after the
Closing but before January 1, 2023: (i) with the total number of the newly issued Equity Securities accounting for 8% of the share capital of the Company immediately after the closing of such Qualified Financing on an as converted and fully
diluted basis; and (ii) with an implied pre-money valuation of the Company of an amount at least US$2,472,850,866. 

 

	123.	 The term “Qualified IPO” means the closing of a firm commitment underwritten initial public
offering of the Ordinary Shares (or securities representing Ordinary Shares) on a Recognized Exchange which meets the following requirements (or otherwise waived by the Majority Series C Preferred Shares Holders): (i) such closing shall take place
on or prior to the third (3rd) anniversary of the date of the first sale and issuance of the Series C Preferred Shares, (ii) the pre-offering valuation
of the Company shall be at least US$1,442,496,338; and (iii) the post-offering public float shall not be less than 10% of the total issued capital of the Company. 

 

	124.	 The term “Qualified Purchasers” has the meaning ascribed to such term in
Section 6.1(c)(ii). 

  

	125.	 The term “Re-allotment Notice” has the meaning
ascribed to such term in Section 6.2(b)(iv). 

  

	126.	 The term “Recognized Exchange” means the main board of the Stock Exchange of Hong Kong
Limited, NASDAQ, New York Stock Exchange or another internationally recognized securities exchange agreed by the Company and the Majority Preferred Shares Holders. 

 

	127.	 The term “Remaining Transfer Share” as the meaning ascribed to such term in
Section 6.2(b)(iv). 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-9 

	128.	 The term “register,” “registered,” and “registration” refer
to a registration effected by preparing and filing a registration statement which is in a form which complies with, and is declared effective by the SEC in accordance with, the Securities Act. 

 

	129.	 The term “Registrable Securities” means: (1) any Ordinary Shares of the Company issued or
issuable pursuant to conversion of any Preferred Shares, (2) any Ordinary Shares of the Company issued (or issuable upon the conversion or exercise of any warrant, right or other security which is issued) as a dividend or other distribution
with respect to, or in exchange for or in replacement of, any Preferred Shares, and (3) any other Ordinary Shares owned or hereafter acquired by an Investor. Notwithstanding the foregoing, “Registrable Securities” shall exclude any
Registrable Securities sold by a person in a transaction in which rights under Appendix B are not assigned in accordance with this Agreement and any Registrable Securities which are sold in a registered public offering under the Securities
Act or analogous statute of another jurisdiction, or sold pursuant to Rule 144 promulgated under the Securities Act or analogous rule of another jurisdiction. 

 

	130.	 The term “Registrable Securities then Outstanding” means the number of Ordinary Shares of the
Company that are Registrable Securities and are then issued and outstanding, issuable upon conversion of Preferred Shares then issued and outstanding or issuable upon conversion or exercise of any warrant, right or other security then outstanding.

  

	131.	 The term “Registration Expenses” shall mean all expenses incurred by the Company in complying
with Section 2, Section 3 and Section 4 of Appendix B, including, without limitation, all registration and filing fees, printing expenses, fees, and disbursements
of counsel for the Company, reasonable fees and disbursements of one (1) counsel for the Holders, “blue sky” fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding the
compensation of regular employees of the Company which shall be paid in any event by the Company). 

  

	132.	 The term “Related Party” has the meaning ascribed to such term in the Purchase Agreement.

  

	133.	 The term “Request Notice” has the meaning ascribed to such term in
Section 2.1 of Appendix B. 

  

	134.	 The term “Right of Co-Sale” means the right, but not
an obligation, of each Investor to participate in a Proposed Transfer on the terms and conditions specified in the Proposed Transfer Notice. 

  

	135.	 The term “Right of First Refusal” has the meaning ascribed to such term in
Section 6.2(b)(i). 

  

	136.	 The term “RMB” means Renminbi, the lawful currency of the People’s Republic of China.

  

	137.	 The term “SAFE” means the State Administration of Foreign Exchange of the PRC.

  

	138.	 The term “SAFE Circular 7” means the Notice of the State Administration of Foreign Exchange on
the Relevant Issues Concerning the Administration of Foreign Exchange for Domestic Individuals’ Participation in Equity Incentive Programs of Overseas Listed Companies
(《国家外汇管理局关于境内个人参与境外上市公司股权激励计划外汇管理有关问题的通知》).
 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-10 

	139.	 The term “SAFE Rules and Regulations” means collectively, the Circular 37, SAFE Circular 7 and
any other applicable SAFE rules and regulations, as amended 

  

	140.	 The term “Sale Notice” has the meaning ascribed to such term in
Section 6.1(c)(i). 

  

	141.	 The term “Sanctions” has the meaning ascribed to such term in
Section 7.13(a). 

  

	142.	 The term “SEC” means the United States Securities and Exchange Commission, or comparable
regulatory authority in any other jurisdiction having oversight over the trading of the Company’s Shares. 

  

	143.	 The term “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act (or
comparable law in a jurisdiction other than the United States). 

  

	144.	 The term “SEC Rule 144(k)” means Rule 144(k) promulgated by the SEC under the Securities Act
(or comparable law in a jurisdiction other than the United States). 

  

	145.	 The term “Securities Act” means the United States Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder, (or comparable law in a jurisdiction other than the United States). 

  

	146.	 The term “Security Holder” has the meaning ascribed to such term in
Section 8.20. 

  

	147.	 The term “Selling Expenses” shall mean all underwriting discounts and selling commissions
applicable to the sale of Registrable Securities pursuant to Section 2, Section 3 and Section 4 of Appendix B. 

 

	148.	 The term “Series A Closing” shall mean June 20, 2014. 

 

	149.	 The term “Series A Preferred Shares” has the meaning ascribed to such term in the Purchase
Agreement. 

  

	150.	 The term “Series A+ Preferred Shares” has the meaning ascribed to such term in the Purchase
Agreement. 

  

	151.	 The term “Series A+ Closing” shall mean August 27, 2015. 

 

	152.	 The term “Series B Preferred Shares” has the meaning ascribed to such term in the Purchase
Agreement. 

  

	153.	 The term “Series C Preferred Shares” has the meaning ascribed to such term in the Purchase
Agreement. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-11 

	154.	 The term “Series C+ Preferred Shares” has the meaning ascribed to such term in the Purchase
Agreement. 

  

	155.	 The term “Sequoia Director” has the meaning ascribed to such term in
Section 5.1(b). 

  

	156.	 The term “Sequoia” shall mean SCC Venture VI Holdco, Ltd. and SCC Venture V Holdco I, Ltd.

  

	157.	 The term “Shanghai Subsidiary” has the meaning ascribed to such term in the Preamble to this
Agreement. 

  

	158.	 The term “Shareholder” shall mean any holder of the Company’s shares.

  

	159.	 The term “Shares” means (i) Ordinary Shares (whether now outstanding or hereafter issued
in any context), (ii) Ordinary Shares issued or issuable upon conversion of the Preferred Shares (iii) Ordinary Shares issued or issuable upon exercise or conversion, as applicable, of share options, warrants or other convertible
securities of the Company and (iv) the Preferred Shares, in each case now owned or subsequently acquired by any Shareholder, or their respective successors or permitted transferees or assigns. 

 

	160.	 The term “Subsidiary” or “subsidiary” means, as of the relevant date of
determination, with respect to any Person (the “subject entity”), (i) any Person: (1) more than 50% of whose shares or other interests entitled to vote in the election of directors or (2) more than a fifty percent (50%) interest
in the profits or capital of such Person are owned or controlled directly or indirectly by the subject entity or through one (1) or more Subsidiaries of the subject entity, (ii) any Person whose assets, or portions thereof, are
consolidated with the net earnings of the subject entity and are recorded on the books of the subject entity for financial reporting purposes in accordance with PRC GAAP, or (iii) any Person with respect to which the subject entity has the
power to otherwise direct the business and policies of that entity directly or indirectly through another subsidiary. For the avoidance of doubt, the Subsidiaries of the Company shall include the Group Companies. 

 

	161.	 The term “Trade Sale” means (1) (A) any consolidation, amalgamation, scheme of arrangement or
merger of a Group Company with or into any other Person or other reorganization in which the members or shareholders of such Group Company immediately prior to such consolidation, amalgamation, merger, scheme of arrangement or reorganization own
less than a majority of such Group Company’s voting power in the aggregate immediately after such consolidation, merger, amalgamation, scheme of arrangement or reorganization, or (B) any transaction or series of related transactions to
which a Group Company is a party in which fifty percent (50%) or more of such Group Company’s voting power or equity interest is transferred; or (2) a sale, transfer, lease or other disposition of all or substantially all of the assets or
business of the Group Companies taken as a whole (or any series of related transactions resulting in such sale, transfer, lease or other disposition of all or substantially all of the assets of the Group Companies taken as a whole), including the
exclusive licensing of all or substantially all of the Group Companies’ intellectual property to a third party. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-12 

	162.	 The term “Transaction Documents” has the meaning ascribed to such term in the Purchase
Agreement. 

  

	163.	 The term “Transaction Terms” has the meaning ascribed to such term in
Section 3.6(a). 

  

	164.	 The term “Transfer” has the meaning ascribed to such term in
Section 6.1(a). 

  

	165.	 The term “Transfer Notice” has the meaning ascribed to such term in
Section 6.2(c)(iv). 

  

	166.	 The term “Transfer Shares” has the meaning ascribed to such term in
Section 6.2(a). 

  

	167.	 The term “Transferred Preferred Shares” has the meaning ascribed to such term in
Section 6.1(c)(i). 

  

	168.	 The term “Transferor” has the meaning ascribed to such term in
Section 6.2(a). 

  

	169.	 The term “Unique” means Unique Invest Co., Ltd. 

 

	170.	 The term “United States Person” means any person described in Section 7701(a)(30) of the
Code. 

  

	171.	 The term “Unsold Transfer Share” has the meaning ascribed to such term in
Section 6.2(f). 

  

	172.	 The term “US$” means the United States dollar, the lawful currency of the United States of
America. 

  

	173.	 The term “U.S. Investor” means (A) any Investor that is a United States Person and
(B) any Investor, one or more of the owners of which are, or controlled by, United States Persons. 

  

	174.	 The term “Violation” has the meaning ascribed to such term in
Section 8.1 of Appendix B. 

  

	175.	 The term “WFOE” has the meaning ascribed to such term in the Preamble to this Agreement.

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX A-13 

 APPENDIX B 

REGISTRATION RIGHTS 
  

	1.	 Applicability of Rights; Non-U.S. Registrations.

  

	1.1	 The Holders (as defined in the Appendix A of this Agreement) shall be entitled to the following rights with
respect to any potential public offering of the Company’s Ordinary Shares in the United States and shall be entitled to reasonably analogous or equivalent rights with respect to any other offering of Company securities in any other jurisdiction
pursuant to which the Company undertakes to publicly offer or list such securities for trading on a recognized securities exchange. 

  

	1.2	 For purposes of this Agreement and Appendix B, reference to registration of securities under the
Securities Act and the Exchange Act shall be deemed to mean the equivalent registration in a jurisdiction other than the United States as designated by such Holders, it being understood and agreed that in each such case all references in this
Agreement to the Securities Act, the Exchange Act and rules, forms of registration statements and registration of securities thereunder, U.S. law and the SEC, shall be deemed to refer, to the equivalent statutes, rules, forms of registration
statements, registration of securities and laws of and equivalent government authority in the applicable non-U.S. jurisdiction. 

 

	2.	 Demand Registration. 

 

	2.1	 Request by Holders. 

If the Company shall, at any time after the earlier of (i) five (5) years after the Series A+ Closing or (ii) six (6) months
following the taking effect of a registration statement for the Company’s initial public offering, receive a written request from the Holders of at least ten percent (10%) of the Registrable Securities then outstanding that the Company file a
registration statement under the Securities Act covering the registration of at least fifteen percent (15%) of the Registrable Securities pursuant to this Section 2, then the Company shall, within ten (10) business
days of the receipt of such written request, give written notice of such request (the “Request Notice”) to all Holders, and use its best efforts to effect, as soon as practicable, the registration under the Securities Act of all
Registrable Securities that the Holders request to be registered and included in such registration by written notice given by such Holders to the Company within twenty (20) days after receipt of the Request Notice, subject only to the
limitations of this Section 2; provided that the Company shall not be obligated to effect any such registration if the Company has, within the six (6) month period preceding the date of such request, already
effected a registration under the Securities Act pursuant to this Section 2 or Section 4 or in which the Holders had an opportunity to participate pursuant to the provisions of
Section 3, other than a registration from which the Registrable Securities of the Holders have been excluded (with respect to all or any portion of the Registrable Securities the Holders requested be included in such
registration) pursuant to the provisions of Sections 2.2(b) or 3.2(b). 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--1 

	2.2	 Underwriting. 

 

	 	(a)	 If the Holders initiating the registration request under this Section 2 (the
“Initiating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, then they shall so advise the Company as a part of their request made pursuant to this
Section 2 and the Company shall include such information in the Request Notice. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided
herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter or underwriters selected for such underwriting by the Holders of a
majority of the Registrable Securities being registered and reasonably acceptable to the Company. 

  

	 	(b)	 Notwithstanding any other provision of this Section 2, if the underwriter(s)
advise(s) the Company in writing that marketing factors require a limitation of the number of securities to be underwritten then the Company shall so advise all Holders of Registrable Securities which would otherwise be registered and underwritten
pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be reduced as required by the underwriter(s) and allocated (i) first, to the Investors on a pro rata basis according to the number of
Registrable Securities then outstanding held by each Investor requesting registration and (ii) then, to the other Holders of Registrable Securities on a pro rata basis according to the number of Registrable Securities then outstanding held by
each such Holder requesting registration; provided, however, that the number of shares of Registrable Securities to be included in such underwriting and registration shall not be reduced unless all other securities are first entirely excluded from
the underwriting and registration including, without limitation, all shares that are not Registrable Securities and are held by any other person, including, without limitation, any person who is an employee, officer or director of the Company or any
Subsidiary of the Company; provided further, that at least twenty-five percent (25%) of shares of Registrable Securities requested by the Holders to be included in such underwriting and registration shall be so included. If any Holder disapproves of
the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter(s), delivered at least ten (10) business days prior to the effective date of the registration statement. Any
Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--2 

	2.3	 Maximum Number of Demand Registrations. 

The Company shall not be obligated to effect more than three (3) such registrations pursuant to this Section 2.

  

	2.4	 Deferral. 

Notwithstanding the foregoing, if the Company shall furnish to Holders requesting registration pursuant to this
Section 2, a certificate signed by the president or chief executive officer of the Company stating that in the good faith judgment of the Board, it would be materially detrimental to the Company and its shareholders for
such registration statement to be filed at such time, then the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of the Initiating Holders; provided,
however, that the Company may not utilize this right more than once in any twelve (12) month period; provided further, that the Company shall not register any other of its shares during such twelve (12) month period. A
demand right shall not be deemed to have been exercised until such deferred registration shall have been effected. 
  

	3.	 Piggyback Registrations. 

 

	3.1	 The Company shall notify all Holders of Registrable Securities in writing at least thirty (30) days prior
to filing any registration statement under the Securities Act for purposes of effecting a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of the
Company, but excluding registration statements relating to any registration under Section 2 or Section 3 of this Agreement or to any employee benefit plan or a corporate reorganization) and shall
afford each such Holder an opportunity to include in such registration statement all or any part of the Registrable Securities then held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the
Registrable Securities held by it shall within twenty (20) days after receipt of the above-described notice from the Company, so notify the Company in writing, and in such notice shall inform the Company
of the number of Registrable Securities such Holder wishes to include in such registration statement. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder
shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms
and conditions set forth herein. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--3 

	3.2	 Underwriting. 

 

	 	(a)	 If a registration statement under which the Company gives notice under this Section 3
is for an underwritten offering, then the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder’s Registrable Securities to be included in a registration pursuant to this
Section 3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders
proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter or underwriters selected for such underwriting. 

 

	 	(b)	 Notwithstanding any other provision of this Agreement, if the managing underwriter(s) determine(s) in good
faith that marketing factors require a limitation of the number of shares to be underwritten, then the managing underwriter(s) may exclude shares from the registration and the underwriting, and the number of shares that may be included in the
registration and the underwriting shall be allocated, first, to the Company, second, to each of the Investors requesting inclusion of their Registrable Securities in such registration statement on a pro rata basis based on the total number of shares
of Registrable Securities then held by each such Investor, third, to the other Holders requesting inclusion of their Registrable Securities in such registration statement on a pro rata basis based on the total number of shares of Registrable
Securities then held by each such Holder and fourth, to holders of other securities of the Company; provided, however, that the right of the underwriter(s) to exclude shares (including Registrable Securities) from the registration and underwriting
as described above shall be restricted so that (i) the number of Registrable Securities included in any such registration is not reduced below thirty percent (30%) of the aggregate number of shares of Registrable Securities for which inclusion
has been requested; and (ii) all shares that are not Registrable Securities and are held by any other person, including, without limitation, any person who is an employee, officer or director of the Company (or any Subsidiary of the Company)
shall first be excluded from such registration and underwriting before any Registrable Securities are so excluded, unless otherwise approved by the holders of a majority of the Registrable Securities. If any Holder disapproves of the terms of any
such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter(s), delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable
Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--4 

	3.3	 Not Demand Registration. 

Registration pursuant to this Section 3 shall not be deemed to be a demand registration as described in
Section 2 above. There shall be no limit on the number of times the Holders may request registration of Registrable Securities under this Section 3. 

 

	4.	 Form F-3 Registration. 

In case the Company shall receive from any Holder or Holders a written request or requests that the Company effect a registration on Form F-3 (or an equivalent registration in a jurisdiction outside of the United States) and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or
Holders, then the Company will: 
  

	4.1	 Notice. 

Promptly give written notice of the proposed registration and the Holder’s or Holders’ request therefor, and any related
qualification or compliance, to all other Holders of Registrable Securities; and 
  

	4.2	 Registration. 

As soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as would permit or
facilitate the sale and distribution of all or such portion of such Holders or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders
joining in such request as are specified in a written request given within twenty (20) days after the Company provides the notice contemplated by Section 4.1; provided, however, that the Company shall not be obligated
to effect any such registration, qualification or compliance pursuant to this Section 4: 
  

	 	(a)	 if Form F-3 is not available for such offering by the Holders;

  

	 	(b)	 if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such
registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than US$500,000; 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--5 

	 	(c)	 if the Company shall furnish to the Holders a certificate signed by the president or chief executive officer of
the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be materially detrimental to the Company and its shareholders for such Form F-3 Registration to be
effected at such time, in which event the Company shall have the right to defer the filing of the Form F-3 registration statement no more than once during any twelve (12) month period for a period of not
more than sixty (60) days after receipt of the request of the Holder or Holders under this Section 4; provided that the Company shall not register any of its other shares during such sixty (60) day period.

  

	 	(d)	 if the Company has, within the six (6) month period preceding the date of such request, already effected a
registration under the Securities Act other than a registration from which the Registrable Securities of Holders have been excluded (with respect to all or any portion of the Registrable Securities the Holders requested be included in such
registration) pursuant to the provisions of Sections 2.2 and 3.2; or 

  

	 	(e)	 in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a
general consent to service of process in effecting such registration, qualification or compliance. 

  

	4.3	 Not a Demand Registration. 

Form F-3 registrations shall not be deemed to be demand registrations as described in
Section 2 above. Except as otherwise provided herein, there shall be no limit on the number of times the Holders may request registration of Registrable Securities under this Section 4. 

 

	4.4	 Underwriting. 

If the Holders of Registrable Securities requesting registration under this Section 4 intend to distribute the
Registrable Securities covered by their request by means of an underwriting, the provisions of Section 2.2 shall apply to such registration. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--6 

	5.	 Expenses.  

All Registration Expenses incurred in connection with any registration pursuant to Sections 2, 3 or 4 (but excluding
Selling Expenses) shall be borne by the Company. Each Holder participating in a registration pursuant to Sections 2, 3 or 4 shall bear such Holder’s proportionate share (based on the total number of shares sold in such
registration other than for the account of the Company) of all Selling Expenses or other amounts payable to underwriter(s) or brokers, in connection with such offering by the Holders. Notwithstanding the foregoing, the Company shall not be required
to pay for any expenses of any registration proceeding begun pursuant to Section 2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be
registered, unless the Holders of a majority of the Registrable Securities then outstanding agree that such registration constitutes the use by the Holders of one (1) demand registration pursuant to Section 2 (in which
case such registration shall also constitute the use by all Holders of Registrable Securities of one (1) such demand registration); provided further, however, that if at the time of such withdrawal, the Holders have learned of a material
adverse change in the condition, business, or prospects of the Company not known to the Holders at the time of their request for such registration and have withdrawn their request for registration with reasonable promptness after learning of such
material adverse change, then the Holders shall not be required to pay any of such expenses and such registration shall not constitute the use of a demand registration pursuant to Section 2. 

 

	6.	 Obligations of the Company. 

Whenever required to effect the registration of any Registrable Securities under this Agreement the Company shall, as expeditiously as
reasonably possible: 
  

	6.1	 Registration Statement. 

Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to cause such
registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to ninety (90) days or, in the
case of Registrable Securities registered under Form F-3 in accordance with Rule 415 under the Securities Act or a successor rule, until the distribution contemplated in the registration statement has been
completed; provided, however, that (i) such ninety (90) day period shall be extended for a period of time equal to the period any Holder refrains from selling any securities included in such registration at the request of the
underwriter(s), and (ii) in the case of any registration of Registrable Securities on Form F-3 which are intended to be offered on a continuous or delayed basis, such ninety (90) day period shall be
extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--7 

	6.2	 Amendments and Supplements. 

Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such
registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement. 

 

	6.3	 Prospectuses. 

Furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the
Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of the Registrable Securities owned by them that are included in such registration. 

 

	6.4	 Blue Sky. 

Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws
of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in
any such states or jurisdictions unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 
  

	6.5	 Underwriting. 

In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement in usual and customary
form, with the managing underwriter(s) of such offering. 
  

	6.6	 Notification. 

Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required
to be delivered under the Securities Act of (i) the issuance of any stop order by the SEC in respect of such registration statement, or (ii) the happening of any event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--8 

	6.7	 Opinion and Comfort Letter. 

Furnish, at the request of any Holder requesting registration of Registrable Securities, on the date that such Registrable Securities are
delivered to the underwriter(s) for sale, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes
effective, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering and reasonably
satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and (ii) letters dated as of (1) the effective date of the registration statement covering such Registrable Securities
and (2) the closing date of the offering from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public
offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities. 

 

	7.	 Furnish Information. 

It shall be a condition precedent to the obligations of the Company to take any action pursuant to Sections 2, 3 or 4 that
the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall be required to timely effect the Registration of their
Registrable Securities. 
  

	8.	 Indemnification. 

In the event any Registrable Securities are included in a registration statement under Sections 2, 3 or 4: 

 

	8.1	 By the Company. 

To the extent permitted by law and its memorandum and articles of association as from time to time altered by special resolution, the Company
will indemnify and hold harmless each Holder, its partners, officers, directors, legal counsel, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of
the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other United States federal or state law, insofar as such
losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): 

 

	 	(a)	 any untrue statement or alleged untrue statement of a material fact contained in such registration statement,
including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--9 

	 	(b)	 the omission or alleged omission to state therein a material fact required to be stated therein, or necessary
to make the statements therein not misleading; or 

  

	 	(c)	 any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any United States
federal or state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any United States federal or state securities law in connection with the offering covered by such registration statement;

 and the Company will reimburse each such Holder, its partner, officer, director, legal counsel, underwriter or
controlling person for any legal or other expenses reasonably incurred by them, as incurred, in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity
agreement contained in this Section 8.1 shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent
shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in
conformity with written information furnished expressly for use in connection with such registration by such Holder or any partner, officer, director, counsel, underwriter or controlling person of such Holder. 

 

	8.2	 By Selling Holders. 

To the extent permitted by law, each selling Holder will, if Registrable Securities held by Holder are included in the securities as to which
such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within
the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, directors, officers, legal counsel or any person who controls such Holder
within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, legal counsel, controlling person, underwriter or other such
Holder, partner or director, officer or controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other United States federal or state law, insofar as such losses, claims, damages or liabilities (or
actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly
for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling person, underwriter or other Holder, partner, officer,
director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this
Section 8.2 shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably
withheld; and provided further, that in no event shall any indemnity under this Section 8.2 exceed the net proceeds received by such Holder in the registered offering out of which the applicable Violation
arises. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--10 

	8.3	 Notice. 

Promptly after receipt by an indemnified party under this Section 8 of notice of the commencement of any action
(including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnified party under this Section 8, deliver to the indemnifying party a written notice of the
commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel
mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential conflict of interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver
written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of liability to the indemnified party under this Section 8 to the extent the
indemnifying party is prejudiced as a result thereof, but the omission to so deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 8. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--11 

	8.4	 Contribution. 

In order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any
indemnified party makes a claim for indemnification pursuant to this Section 8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to
appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 8 provides for indemnification in such case, or (ii) contribution
under the Securities Act may be required on the part of any indemnified party in circumstances for which indemnification is provided under this Section 8; then, and in each such case, the indemnified party and the
indemnifying party will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion so that a Holder (together with its related persons) is responsible for the
portion represented by the percentage that the public offering price of its Registrable Securities offered by and sold under the registration statement bears to the public offering price of all securities offered by and sold under such registration
statement, and the Company and other selling Holders are responsible for the remaining portion. The relative fault of the indemnifying Party and of the indemnified Party shall be determined by a court of law by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying Party or by the indemnified Party and the parties’ relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case: (A) no Holder will be required to contribute any amount in excess of the net proceeds to such Holder from
the sale of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement; and (B) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. 
  

	8.5	 Survival. 

The obligations of the Company and Holders under this Section 8 shall survive the completion of any offering of
Registrable Securities in a registration statement, regardless of the expiration of any statutes of limitation or extensions of such statutes. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of
each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in
respect to such claim or litigation. 
  

	9.	 No Registration Rights to Third Parties. 

Without the prior written consent of the Holders of a majority in interest of the Registrable Securities then outstanding, the Company
covenants and agrees that it shall not grant, or cause or permit to be created, for the benefit of any person or entity any registration rights of any kind (whether similar to the demand, “piggyback” or Form
F-3 registration rights described in this Appendix B, or otherwise) relating to any securities of the Company which are senior to, or on a parity with, those granted to the Holders of Registrable
Securities. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--12 

	10.	 Rule 144 Reporting. 

With a view to making available the benefits of certain rules and regulations of the SEC which may at any time permit the sale of the
Registrable Securities to the public without registration or pursuant to a registration on Form F-3, after such time as a public market exists for the Ordinary Shares, the Company agrees to: 

 

	10.1	 Make and keep public information available, as those terms are understood and defined in Rule 144 under the
Securities Act, at all times after the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to the general public; 

 

	10.2	 File with the SEC in a timely manner all reports and other documents required of the Company under the
Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 

  

	10.3	 So long as a Holder owns any Registrable Securities, to furnish to such Holder forthwith upon request
(i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the Company’s initial public offering), the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting requirements), or its qualification as a registrant whose securities may be resold pursuant to Form F-3 (at any time after it so
qualifies), (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents of the Company as a Holder may reasonably request in availing itself of any rule or regulation of the SEC that
permits the selling of any such securities without registration or pursuant to Form F-3. 

  

	11.	 Market Stand-Off. 

Each Shareholder agrees that, so long as it holds any voting securities of the Company, upon request by the Company or the underwriters
managing the initial public offering of the Company’s securities, it will not sell or otherwise transfer or dispose of an interest in any shares of the Ordinary Shares of the Company (other than those permitted to be included in the
registration and other transfers to Affiliates permitted by law) without the prior written consent of the Company or such underwriters, as the case may be, for a period of time specified by the representative of the underwriters not to exceed one
hundred and eighty (180) days from the effective date of the registration statement covering such initial public offering or the pricing date of such offering as may be requested by the underwriters; provided that (a) the forgoing
provisions of this Section shall not apply to the sale of any securities of the Company to an underwriter pursuant to any underwriting agreement, and shall not be applicable to any Holder unless all directors, officers and all other holders of at
least one percent (1%) of the outstanding share capital of the Company (calculated on an as converted to Ordinary Share basis) must be bound by restrictions at least as restrictive as those applicable to any such Holder pursuant to this Section,
(b) this Section shall not apply to a Holder in whole or in part to the extent that any other Person subject to substantially similar restrictions is released in whole or in part, and (c) to the extent not otherwise objected by the
underwriters, the lockup agreements shall permit a Holder to transfer its Registrable Securities to its Affiliates so long as the transferees enter into the same lockup agreement. The Investors agree to execute and deliver to the underwriters a lock-up agreement containing substantially similar terms and conditions as those contained herein. In order to enforce the foregoing covenant, the Company may place restrictive legends on the certificates and impose
stop-transfer instructions with respect to the Registrable Securities of each shareholder (and the shares or securities of every other Person subject to the foregoing restriction) until the end of such period. 

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 APPENDIX B--13 

 SCHEDULE
I-A-1 
 List of Founder 

SCHEDULE I-A-2 

List of Holding Entities 

SCHEDULE I-B 

Part I: List of Management Shareholders 

Part II: YIN Dong and SI Peijing 

SCHEDULE I-C 

List of A Round Financing Investors 

SCHEDULE I-D 

List of A+ Round Financing Investors 

SCHEDULE I-E 

List of B Round Financing Investors 

SCHEDULE I-F 

List of C Round Financing Investors 

SCHEDULE I-G 

List of C+ Round Financing Investors 

SCHEDULE II 

Notices 

 EXHIBIT A 

ADHERENCE AGREEMENT 

This Adherence Agreement (“Adherence Agreement”) is executed by the undersigned (the “Transferee”) pursuant
to the terms of that certain Fifth Amended and Restated Shareholders Agreement dated as of January 10, 2020 (the “Agreement”) by and among Burning Rock Biotech Limited, a Cayman Islands exempted company (the
“Company”) and certain of its shareholders and certain other parties named thereto, and in consideration of the Shares acquired by the Transferee thereunder and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged. Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adherence Agreement, the Transferee agrees as follows: 

1. Acknowledgment. Transferee acknowledges that Transferee is acquiring [number] [Preferred/Ordinary] shares of the Company (the
“Shares”) from [name of transferor] (the “Transferor”), subject to the terms and conditions of the Agreement. 

2. Agreement. Immediately upon transfer of the Shares, Transferee (i) agrees that the Shares acquired by Transferee shall be bound
by and subject to the terms of the Agreement applicable to the Transferor, and (ii) hereby adopts the Agreement with the same force and effect as if Transferee were originally a/an [Ordinary Shareholder thereunder (if transferor is an
Ordinary Shareholder)]/[Key Holder thereunder (if transferor is a Key Holder)]/[Investor thereunder (if transferor is an Investor)]. 

3. Notice. Any notice required or permitted by the Agreement shall be given to Transferee at the address listed beside Transferee’s
signature below. 
 4. Governing Law. This Adherence Agreement shall be governed in all respects by the Laws of the Hong Kong Special
Administrative Region without regard to conflicts of law principles. 
 EXECUTED AND DATED this
             day of
                            ,         . 

 

			
	TRANSFEREE:

 
			
		
	By:	 	  

 
			
	 Name:

	 Title:

	Attn:
	Address:
	Tel:
	Fax:
	Email:

  
 Fifth Amended and Restated
Shareholders’ Agreement 
 EXHIBIT AEX-10.1

 Exhibit 10.1 

INDEMNIFICATION AGREEMENT 

THIS INDEMNIFICIATION AGREEMNT (this “Agreement”) is made as of
            , 20     by and between Burning Rock Biotech Limited, an exempted company with limited liability incorporated and existing under
the laws of the Cayman Islands (the “Company”) and
                             ([Passport/ID] Number
                            ) (the “Indemnitee”). 

WHEREAS, the Indemnitee has agreed to serve as a director or executive officer of the Company and in such capacity will render valuable
services to the Company; and 
 WHEREAS, in order to induce and encourage highly experienced and capable persons such as the Indemnitee to
render valuable services to the Company, the board of directors of the Company (the “Board of Directors”) has determined that this Agreement is not only reasonable and prudent, but necessary to promote and ensure the best interests
of the Company and its shareholders; 
 NOW, THEREFORE, in consideration of the premises and mutual agreements hereinafter set forth, and
other good and valuable consideration, including, without limitation, the service of the Indemnitee, the receipt of which hereby is acknowledged, and in order to induce the Indemnitee to render valuable services to the Company, the Company and the
Indemnitee hereby agree as follows: 
 1. Definitions. As used in this Agreement: 

(a) “Changes in Control” shall mean a change in control of the Company of a nature that would be required to be
reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar or successor schedule or form) promulgated under the United States Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder (collectively, the “Act”), whether or not the Company is then subject to such reporting requirement; provided, however, that, without limitation, such a Change in Control shall be deemed to have
occurred (irrespective of the applicability of the initial clause of this definition) if (i) any “person” (as such term is used in Section 13(d) and 14(d) of the Act, but excluding any trustee or other fiduciary holding
securities pursuant to an employee benefit or welfare plan or employee share plan of the Company or any subsidiary or affiliate of the Company, or any entity organized, appointed, established or holding securities of the Company with voting power
for or pursuant to the terms of any such plan) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 30% or more
of the combined voting power of the Company’s then outstanding securities without the prior approval of at least two-thirds of the Continuing Directors (as defined below) in office immediately prior to
such person’s attaining such interest; (ii) the Company is a party to a merger, consolidation, scheme of arrangement, sale of assets or other reorganization, or a proxy contest, as a consequence of which Continuing Directors in office
immediately prior to such transaction or event constitute less than a majority of the Board of Directors of the Company (or any successor entity) thereafter; or (iii) during any period of two consecutive years, Continuing Directors cease for
any reason to constitute at least a majority of the Board of Directors of the Company. 

  
 1 

 (b) “Continuing Director” shall mean an individual (i) who
served on the Board of Directors of the Company at the effective date of the Company’s registration statement on Form F-1 relating to the Company’s initial public offering; or (ii) whose
election or nomination for election by the Company’s shareholders was approved by a vote of at least two-thirds of the Continuing Directors then in office. 

(c) “Disinterested Director” with respect to any request by the Indemnitee for indemnification, contribution, or
advancement of expenses hereunder shall mean a director of the Company who neither is nor was a party to the Proceeding (as defined below) in respect of which indemnification, contribution, or advancement is being sought by the Indemnitee. 

(d) The term “Expenses” shall mean, without limitation, expenses of Proceedings, including attorneys’ fees,
disbursement and retainers, accounting and witness fees, expenses related to preparation for service as a witness and to service as a witness, travel and deposition costs, expenses of investigations, judicial or administrative proceedings and
appeals, amounts paid in settlement of a Proceeding by or on behalf of the Indemnitee, costs of attachment or similar bonds, any expenses of attempting to establish or establishing a right to indemnification, contribution, or advancement of
expenses, under this Agreement, the Company’s Memorandum of Association and Articles of Association as currently in effect (the “Articles”), applicable law or otherwise, and reasonable compensation for time spent by the
Indemnitee in connection with the investigation, defense or appeal of a Proceeding or action for indemnification for which the Indemnitee is not otherwise compensated by the Company or any third party. The term “Expenses” shall not include
the amount of judgments, fines, interest or penalties, which are actually levied against or sustained by the Indemnitee to the extent sustained after final adjudication. 

(e) The term “Independent Legal Counsel” shall mean any firm of attorneys reasonably selected by the Board of
Directors of the Company, so long as such firm has not represented the Company, the Company’s subsidiaries or affiliates, the Indemnitee, any entity controlled by the Indemnitee, or any party adverse to the Company, within the preceding five
(5) years. Notwithstanding the foregoing, the term “Independent Legal Counsel” shall not include any person who, under applicable standards of professional conduct then prevailing, would have a conflict of interest in representing
either the Company or the Indemnitee in an action to determine the Indemnitee’s right to indemnification, contribution, or advancement of expenses under this Agreement, the Company’s Articles, applicable law or otherwise. 

(f) The term “Proceeding” shall mean any threatened, pending or completed action, suit, arbitration, alternate dispute
resolution mechanism, or other proceeding (including, without limitation, an appeal therefrom), formal or informal, whether brought in the name of the Company or otherwise, whether of a civil, criminal, administrative or investigative nature, and
whether by, in or involving a court or an administrative, other governmental or private entity or body (including, without limitation, an investigation by the Company or its Board of Directors), by reason of (i) the fact that the Indemnitee is
or was a director or officer of the Company, or is or was serving at the request of the Company as an agent of another enterprise, whether or not the Indemnitee is serving in such capacity at the time any liability or expense is incurred for which
indemnification or reimbursement is to be provided under this Agreement, (ii) any actual or alleged act or omission or neglect or breach of duty, including, without limitation, any actual or alleged error or misstatement or misleading
statement, which the Indemnitee commits or suffers while acting in any such capacity, or (iii) the Indemnitee attempting to establish or establishing a right to indemnification, contribution, or advancement of expenses pursuant to this
Agreement, the Company’s Articles, applicable law or otherwise. 

  
 2 

 (g) The phrase “serving at the request of the Company as an agent of another
enterprise” or any similar terminology shall mean, unless the context otherwise requires, serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, limited liability
company, trust, employee benefit or welfare plan or other enterprise, foreign or domestic. The phrase “serving at the request of the Company” shall include, without limitation, any service as a director/an executive officer of the Company
which imposes duties on, or involves services by, such director/executive officer with respect to the Company or any of the Company’s subsidiaries, affiliates, employee benefit or welfare plans, such plan’s participants or beneficiaries or
any other enterprise, foreign or domestic. In the event that the Indemnitee shall be a director, officer, employee or agent of another corporation, partnership, joint venture, limited liability company, trust, employee benefit or welfare plan or
other enterprise, foreign or domestic, 50% or more of the ordinary shares, combined voting power or total equity interest of which is owned by the Company or any subsidiary or affiliate thereof, then it shall be presumed conclusively that the
Indemnitee is so acting at the request of the Company. 
 2. Services by the Indemnitee. The Indemnitee agrees to serve as a
director or officer of the Company, for so long as the Indemnitee is duly elected or appointed or until such time as the Indemnitee tenders a resignation in writing or is removed from the Indemnitee’s position; provided, however, that the
Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or other obligation imposed by operation of law). 

3. Proceedings by or in the Right of the Company. The Company shall indemnify the Indemnitee if the Indemnitee is a party to or
threatened to be made a party to or is otherwise involved in any Proceeding by or in the right of the Company to procure a judgment in its favor by reason of the fact that the Indemnitee is or was a director or officer of the Company, or is or was
serving at the request of the Company as an agent of another enterprise, against all Expenses, judgments, fines, interest or penalties, which are actually and reasonably incurred by the Indemnitee in connection with the defense or settlement of such
a Proceeding, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Company; except that no indemnification under this section shall be made in respect
of any claim, issue or matter as to which such person shall have been adjudicated by final judgment by a court of competent jurisdiction to be liable to the Company for dishonesty, willful misconduct or fraud in the performance of his/her duty to
the Company, unless and only to the extent that the court in which such Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and
reasonably entitled to indemnity for such amounts which such other court shall deem proper. 
 4. Proceeding Other Than a
Proceeding by or in the Right of the Company. The Company shall indemnify the Indemnitee if the Indemnitee is a party to or threatened to be made a party to or is otherwise involved in any Proceeding (other than a Proceeding by or in the right
of the Company) by reason of the fact that the Indemnitee is or was a director or officer of the Company, or is or was serving at the request of the Company as an agent of another enterprise, against all Expenses, judgments, fines, interest or
penalties, which are actually and reasonably incurred by the Indemnitee in connection with such a Proceeding, to the fullest extent permitted by applicable law; provided, however, that any settlement of a Proceeding must be approved in advance in
writing by the Company (which approval shall not be unreasonably withheld). 

  
 3 

 5. Indemnification for Costs, Charges and Expenses of Witness or Successful
Party. Notwithstanding any other provision of this Agreement (except as set forth in subparagraph 9(a) hereof), and without a requirement for determination as required by Paragraph 8 hereof, to the extent that the Indemnitee (a) has
prepared to serve or has served as a witness in any Proceeding in any way relating to (i) the Company or the Company’s subsidiaries, affiliates, employee benefit or welfare plans or such plan’s participants or beneficiaries or
(ii) anything done or not done by the Indemnitee as a director or officer of the Company or in connection with serving at the request of the Company as an agent of another enterprise, or (b) has been successful in defense of any Proceeding
or in defense of any claim, issue or matter therein, on the merits or otherwise, including the dismissal of a Proceeding without prejudice or the settlement of a Proceeding without an admission of liability, the Indemnitee shall be indemnified
against all Expenses actually and reasonably incurred by the Indemnitee in connection therewith to the fullest extent permitted by applicable law. 

6. Partial Indemnification. If the Indemnitee is entitled under any provision of this Agreement to indemnification by the
Company for a portion of the Expenses, judgments, fines, interest or penalties, which are actually and reasonably incurred by the Indemnitee in the investigation, defense, appeal or settlement of any Proceeding, but not, however, for the total
amount of the Indemnitee’s Expenses, judgments, fines, interest or penalties, then the Company shall nevertheless indemnify the Indemnitee for the portion of such Expenses, judgments, fines, interest or penalties to which the Indemnitee is
entitled. 
 7. Advancement of Expenses. The Expenses incurred by the Indemnitee in any Proceeding shall be paid promptly by
the Company in advance of the final disposition of the Proceeding at the written request of the Indemnitee, to the fullest extent permitted by applicable law; provided, however, that the Indemnitee shall set forth in such request reasonable evidence
that such Expenses have been incurred by the Indemnitee in connection with such Proceeding, a statement that such Expenses do not relate to any matter described in subparagraph 9(a) of this Agreement, and an undertaking in writing to repay any
advances if it is ultimately determined as provided in subparagraph 8(b) of this Agreement that the Indemnitee is not entitled to indemnification under this Agreement. 

8. Indemnification Procedure; Determination of Right to Indemnification. 

(a) Promptly after receipt by the Indemnitee of notice of the commencement of any Proceeding, the Indemnitee shall, if a claim for
indemnification or advancement of Expenses in respect thereof is to be made against the Company under this Agreement, notify the Company of the commencement thereof in writing. The failure and delay to so notify the Company will not relieve the
Company from any liability which the Company may have to the Indemnitee under this Agreement unless the Company shall have lost significant substantive or procedural rights with respect to the defense of any Proceeding as a result of such omission
to so notify. 

  
 4 

 (b) The Indemnitee shall be conclusively presumed to have met the relevant standards
of conduct, if any, as defined by applicable law, for indemnification pursuant to this Agreement and shall be absolutely entitled to such indemnification, unless a determination is made that the Indemnitee has not met such standards by (i) the
Board of Directors by a majority vote of a quorum thereof consisting of Disinterested Directors, (ii) the shareholders of the Company by majority vote of a quorum thereof consisting of shareholders who are not parties to the Proceeding due to
which a claim for indemnification is made under this Agreement, (iii) Independent Legal Counsel as set forth in a written opinion (it being understood that such Independent Legal Counsel shall make such determination only if the quorum of
Disinterested Directors referred to in clause (i) of this subparagraph 8(b) is not obtainable or if the Board of Directors of the Company by a majority vote of a quorum thereof consisting of Disinterested Directors so directs), or (iv) a
court of competent jurisdiction; provided, however, that if a Change in Control shall have occurred and the Indemnitee so requests in writing, such determination shall be made only by a court of competent jurisdiction. 

(c) If a claim for indemnification or advancement of Expenses under this Agreement is not paid by the Company within thirty
(30) days after receipt by the Company of written notice thereof, the rights provided by this Agreement shall be enforceable by the Indemnitee in any court of competent jurisdiction. Such judicial proceeding shall be made de novo. The burden of
proving that indemnification or advances are not appropriate shall be on the Company. Neither the failure of the directors or shareholders of the Company or Independent Legal Counsel to have made a determination prior to the commencement of such
action that indemnification or advancement of Expenses is proper in the circumstances because the Indemnitee has met the applicable standard of conduct, if any, nor an actual determination by the directors or shareholders of the Company or
Independent Legal Counsel that the Indemnitee has not met the applicable standard of conduct shall be a defense to an action by the Indemnitee or create a presumption for the purpose of such an action that the Indemnitee has not met the applicable
standard of conduct. The termination of any Proceeding by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself (i) create a presumption that the Indemnitee did not act in
good faith and in a manner which he reasonably believed to be in the best interests of the Company and/or its shareholders, and, with respect to any criminal Proceeding, that the Indemnitee had reasonable cause to believe that his conduct was
unlawful or (ii) otherwise adversely affect the rights of the Indemnitee to indemnification or advancement of Expenses under this Agreement, except as may be provided herein. 

(d) If a court of competent jurisdiction shall determine that the Indemnitee is entitled to any indemnification or advancement of
Expenses hereunder, the Company shall pay all Expenses actually and reasonably incurred by the Indemnitee in connection with such adjudication (including, but not limited to, any appellate proceedings). 

  
 5 

 (e) With respect to any Proceeding for which indemnification or advancement of
Expenses is requested, the Company will be entitled to participate therein at its own expense and, except as otherwise provided below, to the extent that it may wish, the Company may assume the defense thereof, with counsel reasonably satisfactory
to the Indemnitee. After notice from the Company to the Indemnitee of its election to assume the defense of a Proceeding, the Company will not be liable to the Indemnitee under this Agreement for any Expenses subsequently incurred by the Indemnitee
in connection with the defense thereof, other than as provided below. The Company shall not settle any Proceeding in any manner which would impose any penalty or limitation on the Indemnitee without the Indemnitee’s written consent. The
Indemnitee shall have the right to employ his/her own counsel in any Proceeding, but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the defense of the Proceeding shall be at the expense of the
Indemnitee, unless (i) the employment of counsel by the Indemnitee has been authorized by the Company, (ii) the Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in
the conduct of the defense of a Proceeding, or (iii) the Company shall not in fact have employed counsel to assume the defense of a proceeding, in each of which cases the fees and expenses of the Indemnitee’s counsel shall be advanced by
the Company. The Company shall not be entitled to assume the defense of any Proceeding brought by or on behalf of the Company or as to which the Indemnitee has reasonably concluded that there may be a conflict of interest between the Company and the
Indemnitee. 
 9. Limitations on Indemnification. No payments pursuant to this Agreement shall be made by the Company: 

(a) To indemnify or advance funds to the Indemnitee for Expenses with respect to (i) Proceedings initiated or brought voluntarily
by the Indemnitee and not by way of defense, except with respect to Proceedings brought to establish or enforce a right to indemnification or contribution under this Agreement or any other statute or law or otherwise as required under applicable law
or (ii) Expenses incurred by the Indemnitee in connection with preparing to serve or serving as a witness in cooperation with any party or entity who or which has threatened or commenced any action or proceeding against the Company, or any
director, officer, employee, trustee, agent, representative, subsidiary, parent corporation or affiliate of the Company, but such indemnification, contribution or advancement of Expenses in each such case may be provided by the Company if the Board
of Directors finds it to be appropriate; 
 (b) To indemnify the Indemnitee for any Expenses, judgments, fines, interest or penalties
sustained in any Proceeding for which payment is actually made to the Indemnitee under a valid and collectible insurance policy, except in respect of any excess beyond the amount of payment under such insurance; 

(c) To indemnify the Indemnitee for any Expenses, judgments, fines, interest or penalties sustained in any Proceeding for an accounting
of profits made from the purchase or sale by the Indemnitee of securities of the Company pursuant to the provisions of Section 16(b) of the Act or similar provisions of any foreign or United States federal, state or local statute or regulation;

 (d) To indemnify the Indemnitee for any Expenses, judgments, fines, interest or penalties for which the Indemnitee is indemnified
by the Company otherwise than pursuant to this Agreement; 
 (e) To indemnify the Indemnitee for any Expenses (including without
limitation any Expenses relating to a Proceeding attempting to enforce this Agreement), judgments, fines, interest or penalties on account of the Indemnitee’s conduct if such conduct shall be finally adjudged by a court of competent
jurisdiction to have been knowingly fraudulent or deliberately dishonest or to have constituted willful misconduct, including, without limitation, breach of the duty of loyalty; or 

  
 6 

 (f) If a court of competent jurisdiction finally determines that any indemnification
hereunder is unlawful. In this respect, the Company and the Indemnitee have been advised that the Securities and Exchange Commission takes the position that indemnification for liabilities arising under securities laws is against public policy and
is, therefore, unenforceable and that claims for indemnification should be submitted to appropriate courts for adjudication; 
 (g)
To indemnify the Indemnitee in connection with Indemnitee’s personal tax matter; 
 (h) To indemnify the Indemnitee with respect
to any claim related to any dispute or breach arising under any contract or similar obligation between the Company or any of its subsidiaries or affiliates and such Indemnitee; or 

(i) In connection with any reimbursement made by Indemnitee to the Company pursuant to Section 304 of the Sarbanes-Oxley Act of
2002 (the “Sarbanes-Oxley Act”), Section 306 of the Sarbanes-Oxley Act or Section 954 of the Dodd–Frank Wall Street Reform and Consumer Protection Act and the rules promulgated by the SEC thereunder. 

10. Continuation of Indemnification. All agreements and obligations of the Company contained herein shall continue during the
period that the Indemnitee is a director or officer of the Company (or is or was serving at the request of the Company as an agent of another enterprise, foreign or domestic) and shall continue thereafter so long as the Indemnitee shall be subject
to any possible Proceeding by reason of the fact that the Indemnitee was a director or officer of the Company or serving in any other capacity referred to in this Paragraph 10. 

11. Remedies Hereunder Not Exclusive. The indemnification, contribution, and advancement provided by this Agreement shall not be
deemed to be exclusive of any other rights to which the Indemnitee may be entitled under the Company’s Articles, any agreement, vote of shareholders or vote of Disinterested Directors, provisions of applicable law, or otherwise, both as to
action or omission in the Indemnitee’s official capacity and as to action or omission in another capacity on behalf of the Company while holding such office. 

12. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement
is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in
settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect
(a) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (b) the relative fault of the Company (and its directors, officers, employees and
agents) and Indemnitee in connection with such event(s) and/or transaction(s). The relative fault of the Company on the one hand and of the Indemnitee on the other hand shall be determined by reference to, among other things, the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent the circumstances resulting in such judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses. The Company agrees
that it would not be just and equitable if contribution pursuant to this Section 12 were determined by pro rata allocation or any other method of allocation which does not take account of the foregoing equitable considerations. 

  
 7 

 13. Successors and Assigns. 

(a) This Agreement shall be binding upon the Indemnitee, and shall inure to the benefit of, the Indemnitee and the Indemnitee’s
heirs, executors, administrators and assigns, whether or not the Indemnitee has ceased to be a director or officer, and the Company and its successors and assigns. Upon the sale of all or substantially all of the business, assets or share capital of
the Company to, or upon the merger of the Company into or with, any corporation, partnership, joint venture, trust or other person, this Agreement shall inure to the benefit of and be binding upon both the Indemnitee and such purchaser or successor
person. Subject to the foregoing, this Agreement may not be assigned by either party without the prior written consent of the other party hereto. 

(b) If the Indemnitee is deceased and is entitled to indemnification under any provision of this Agreement, the Company shall indemnity
the Indemnitee’s estate and the Indemnitee’s spouse, heirs, executors, administrators and assigns against, and the Company shall, and does hereby agree to assume, any and all Expenses actually and reasonably incurred by or for the
Indemnitee or the Indemnitee’s estate, in connection with the investigation, defense, appeal or settlement of any Proceeding. Further, when requested in writing by the spouse of the Indemnitee, and/or the Indemnitee’s heirs, executors,
administrators and assigns, the Company shall provide appropriate evidence of the Company’s agreement set out herein to indemnify the Indemnitee against and to itself assume such Expenses. 

14. Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to
all of the rights of recovery of the Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such rights. 

15. Severability. Each and every paragraph, sentence, term and provision of this Agreement is separate and distinct so that if
any paragraph, sentence, term or provision thereof shall be held to be invalid, unlawful or unenforceable for any reason, such invalidity, unlawfulness or unenforceability shall not affect the validity, unlawfulness or enforceability of any other
paragraph, sentence, term or provision hereof. To the extent required, any paragraph, sentence, term or provision of this Agreement may be modified by a court of competent jurisdiction to preserve its validity and to provide the Indemnitee with the
broadest possible indemnification permitted under applicable law. The Company’s inability, pursuant to a court order or decision, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. 

16. Savings Clause. If this Agreement or any paragraph, sentence, term or provision hereof is invalidated on any ground by any
court of competent jurisdiction, the Company shall nevertheless indemnify the Indemnitee as to any Expenses, judgments, fines, interest or penalties, which are incurred with respect to any Proceeding to the fullest extent permitted by any
(a) applicable paragraph, sentence, term or provision of this Agreement that has not been invalidated or (b) applicable law. 

  
 8 

 17. Interpretation; Governing Law. This Agreement shall be construed as a
whole and in accordance with its fair meaning and any ambiguities shall not be construed for or against either party. Headings are for convenience only and shall not be used in construing meaning. This Agreement shall be governed and interpreted in
accordance with the laws of the State of New York, U.S.A. 
 18. Amendments. No amendment, waiver, modification, termination
or cancellation of this Agreement shall be effective unless in writing signed by the party against whom enforcement is sought. The rights afforded to the Indemnitee with respect to indemnification, contribution or advancement hereby are contract
rights and may not be diminished, eliminated or otherwise affected by amendments to the policies, of the Company. 
 19.
Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each party and delivered to the
other. 
 20. Notices. Any notice required to be given under this Agreement shall be directed to the Company at 601, 6/F,
Building 3, Standard Industrial Unit 2, No.7 Luoxuan 4th Road, International Bio Island, Guangzhou, the People’s Republic of China, and to the Indemnitee at ______________________________________, or to such other address as either shall
designate to the other in writing. 
 [The remainder of this page is intentionally left blank.] 

  
 9 

 IN WITNESS WHEREOF, the parties have executed this Indemnification Agreement as of the date first written
above. 
  

	
	INDEMNITEE
	
	 
	Name:

  

			
	Burning Rock Biotech Limited

			
		
	By:	 	 

			
	Name:	 	
	Title:	 	

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]